TY 2020 Form 990

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W-2/1099-MISC)
(1) RICHARD W BROWN...................................................................... DIRECTOR/CHAIR	2.0 ................. 46.0	X	X		0	2,581,339	63,694
(2) RODERICK L STURGEON...................................................................... DIRECTOR/CFO	2.0 ................. 48.0	X	X		0	1,725,854	66,518
(3) DAVID A WELTE...................................................................... DIRECTOR/SECRETARY	2.0 ................. 48.0	X	X		0	1,426,753	72,966
(4) DAVID M CHAO...................................................................... DIR/PRESIDENT/CEO TIL 10/2020	32.0 ................. 10.0	X	X		846,761	273,442	44,290
(5) CHARLES GERMAN...................................................................... DIRECTOR AS OF 10/29/2020	1.0 ................. 40.0	X			0	652,268	59,392
(6) BRENT KREIDER...................................................................... CHIEF OPERATING OFFICER	2.0 ................. 40.0		X		0	599,082	69,189
(7) ROBERT E KRUMLAUF...................................................................... SCIENTIFIC DIRECTOR EMERITUS	40.0 ................. 0.0			X	556,677	0	64,964
(8) MICHAEL P WASHBURN...................................................................... INVESTIGATOR	40.0 ................. 0.0			X	557,768	0	27,507
(9) R SCOTT HAWLEY...................................................................... INVESTIGATOR	40.0 ................. 0.0			X	370,653	0	63,771
(10) JERRY L WORKMAN...................................................................... INVESTIGATOR	40.0 ................. 0.0			X	371,766	0	55,447
(11) JOAN W CONAWAY...................................................................... INVESTIGATOR	40.0 ................. 0.0			X	329,279	0	63,722
(12) ALEJANDRO SANCHEZ ALVARADO...................................................................... DIR/CHIEF SCIENTIFIC OFFICER	40.0 ................. 4.0	X			153,798	0	15,703
(13) VIRGINIA G STOWERS...................................................................... DIRECTOR	2.0 ................. 2.0	X			0	0	0
(14) ALBERZINE FREEMAN...................................................................... DIRECTOR	2.0 ................. 4.0	X			0	0	0
(15) JONATHAN THOMAS...................................................................... DIRECTOR	2.0 ................. 4.0	X			0	0	0

- TIN:

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2020

Open to Public
Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990 or 990-EZ).)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

SEE SCHEDULE A

PART VI

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An agricultural research organization described in 170(b)(1)(A)(ix) operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:

An organization that normally receives: (1) more than 331/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box in lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

Type I. A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete Part IV, Sections A and B.

Type II. A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete Part IV, Sections A and C.

Type III functionally integrated. A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete Part IV, Sections A, D, and E.

Type III non-functionally integrated. A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete Part IV, Sections A and D, and Part V.

Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

Enter the number of supported organizations ...............................

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
(i) Name of supported organization	(ii) EIN	Yes	No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)


Total

For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.

Cat. No. 11285F

Schedule A (Form 990 or 990-EZ) 2020

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2016	(b) 2017	(c) 2018	(d) 2019	(e) 2020	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") ..
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..
6	Public support. Subtract line 5 from line 4.

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2016	(b) 2017	(c) 2018	(d) 2019	(e) 2020	(f) Total
7	Amounts from line 4..
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)..
11	Total support. Add lines 7 through 10

Gross receipts from related activities, etc. (see instructions) ..................

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2020 (line 6, column (f) divided by line 11, column (f)) .........

Public support percentage for 2019 Schedule A, Part II, line 14 ...............

16a

33 1/3% support test—2020. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2019. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2020. If the organization did not check a box on line 13, 16a, or 16b, and line 14
is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain
in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported
organization ..................................................... right arrow

10%-facts-and-circumstances test—2019. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line
15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here.
Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly
supported organization ................................................ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990 or 990-EZ) 2020

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2016	(b) 2017	(c) 2018	(d) 2019	(e) 2020	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose
3	Gross receipts from activities that are not an unrelated trade or business under section 513 .....
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge
6	Total. Add lines 1 through 5
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2016	(b) 2017	(c) 2018	(d) 2019	(e) 2020	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization,
check this box and stop here............................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2020 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2019 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2020 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2019 Schedule A, Part III, line 17 .............

19a

331/3% support tests—2020. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ....... right arrow

33 1/3% support tests—2019. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions .... right arrow

Schedule A (Form 990 or 990-EZ) 2020

Page 4

Part IV

Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, of Part I, complete Sections A and B. If you checked box 12b, of Part I, complete Sections A and C. If you checked box 12c, of Part I, complete Sections A, D, and E. If you checked box12d, of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

Yes

Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.

Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).

Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.

Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.

Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.

Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.

Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.

Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.

Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).

Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?

Substitutions only. Was the substitution the result of an event beyond the organization's control?

Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.

Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990 or 990-EZ) .

Did the organization make a loan to a disqualified person (as defined in section 4958) not described in line 7? If “Yes,” complete Part I of Schedule L (Form 990 or 990-EZ).

Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.

Did one or more disqualified persons (as defined in line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.

Did a disqualified person (as defined in line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.

10a

Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.

10a

Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).

10b

Schedule A (Form 990 or 990-EZ) 2020

Page 5

Part IV

Supporting Organizations (continued)

Yes

Has the organization accepted a gift or contribution from any of the following persons?

A person who directly or indirectly controls, either alone or together with persons described in lines 11b and 11c below, the governing body of a supported organization?

11a

A family member of a person described in 11a above?

11b

A 35% controlled entity of a person described in line 11a or 11b above? If “Yes” to 11a, 11b, or 11c, provide detail in Part VI.

11c

Section B. Type I Supporting Organizations

Yes

Did the officers, directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.

Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.

Section C. Type II Supporting Organizations

Yes

Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

Section D. All Type III Supporting Organizations

Yes

Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?

Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).

By reason of the relationship described in line 2 above, did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.

Section E. Type III Functionally-Integrated Supporting Organizations

Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):

The organization satisfied the Activities Test. Complete line 2 below.

The organization is the parent of each of its supported organizations. Complete line 3 below.

The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions)

Activities Test. Answer lines 2a and 2b below.

Yes

Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.

Did the activities described in line 2a, above constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.

Parent of Supported Organizations. Answer lines 3a and 3b below.

Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations?If "Yes" or "No", provide details in Part VI.

Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? If "Yes," describe in Part VI. the role played by the organization in this regard.

Schedule A (Form 990 or 990-EZ) 2020

Page 6

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

	Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1
2	Recoveries of prior-year distributions	2
3	Other gross income (see instructions)	3
4	Add lines 1 through 3	4
5	Depreciation and depletion	5
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6
7	Other expenses (see instructions)	7
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8

	Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1
a	Average monthly value of securities	1a
b	Average monthly cash balances	1b
c	Fair market value of other non-exempt-use assets	1c
d	Total (add lines 1a, 1b, and 1c)	1d
e	Discount claimed for blockage or other factors (explain in detail in Part VI):
2	Acquisition indebtedness applicable to non-exempt use assets	2
3	Subtract line 2 from line 1d	3
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5
6	Multiply line 5 by 0.035	6
7	Recoveries of prior-year distributions	7
8	Minimum Asset Amount (add line 7 to line 6)	8

	Section C - Distributable Amount		Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1
2	Enter 85% of line 1	2
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3
4	Enter greater of line 2 or line 3	4
5	Income tax imposed in prior year	5
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6

Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions)

Schedule A (Form 990 or 990-EZ) 2020

Page 7

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	1
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4 Amounts paid to acquire exempt-use assets	4
5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	5
6 Other distributions (describe in Part VI). See instructions	6
7Total annual distributions. Add lines 1 through 6.	7
8 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions	8
9 Distributable amount for 2020 from Section C, line 6	9
10 Line 8 amount divided by Line 9 amount	10

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2020	(iii) Distributable Amount for 2020
1 Distributable amount for 2020 from Section C, line 6
2 Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions.
3 Excess distributions carryover, if any, to 2020:
a From 2015.......
b From 2016.......
c From 2017.......
d From 2018.......
e From 2019.......
fTotal of lines 3a through e
g Applied to underdistributions of prior years
h Applied to 2020 distributable amount
i Carryover from 2015 not applied (see instructions)
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.
4Distributions for 2020 from Section D, line 7:
$
a Applied to underdistributions of prior years
b Applied to 2020 distributable amount
c Remainder. Subtract lines 4a and 4b from line 4.
5 Remaining underdistributions for years prior to 2020, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions.
6 Remaining underdistributions for 2020. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions.
7 Excess distributions carryover to 2021. Add lines 3j and 4c.
8 Breakdown of line 7:
a Excess from 2016.....
b Excess from 2017.....
c Excess from 2018.....
d Excess from 2019.....
e Excess from 2020.....

Schedule A (Form 990 or 990-EZ) (2020)

Schedule A (Form 990 or 990-EZ) 2020

Page 8

Part VI

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Return Reference	Explanation
PART I, LINE 4	STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") CONDUCTS MEDICAL RESEARCH IN CONJUNCTION WITH THE UNIVERSITY OF KANSAS (KU) AND ITS AFFILIATES, THE UNIVERSITY OF KANSAS HOSPITAL AUTHORITY AND THE UNIVERSITY OF KANSAS MEDICAL CENTER (KUMC), PURSUANT TO A WRITTEN MEMORANDUM OF UNDERSTANDING. KUMC IS THE ACADEMIC HEALTH SCIENCE CENTER OF THE LARGEST PUBLIC RESEARCH UNIVERSITY IN THE STATE OF KANSAS. KUMC OFFERS PROGRAMS AND SERVICES THAT FOCUS ON EDUCATION, RESEARCH, PATIENT CARE, AND COMMUNITY ENGAGEMENT. AS OF DECEMBER 31, 2020, FIVE KUMC STUDENTS HAVE RECEIVED MS DEGREES AND FORTY-SIX KUMC STUDENTS HAVE RECEIVED PHD DEGREES FOR THESIS WORK PERFORMED IN SIMR LABS. KUMC IS AFFILIATED WITH THE UNIVERSITY OF KANSAS HOSPITAL, A NONPROFIT INDEPENDENT HOSPITAL CO-LOCATED WITH THE MAIN KUMC CAMPUS IN KANSAS CITY, KS. IN 2020, TWENTY SIMR RESEARCH PROGRAM LEADERS WERE ADJUNCT FACULTY IN FOUR KUMC DEPARTMENTS. THESE APPOINTMENTS INCLUDED TWELVE FULL PROFESSORS, FOUR ASSOCIATE PROFESSORS, AND FOUR ASSISTANT PROFESSORS. IN 2020, FORTY-EIGHT OF SIMR'S FIFTY-NINE ORIGINAL RESEARCH PUBLICATIONS INCLUDED BOTH SIMR AND KUMC AFFILIATIONS. ABOUT A DOZEN KUMC STUDENTS PERFORMED PREDOCTORAL RESEARCH IN SIMR LABS IN 2020. SIMR IS ALSO A CONSORTIUM MEMBER OF THE UNIVERSITY OF KANSAS CANCER CENTER AT KUMC, A CANCER RESEARCH AND CARE PARTNERSHIP SPANNING TWO STATES AND INVOLVING COLLABORATION AMONG RESEARCHERS, PHYSICIANS, AND CANCER SUPPORT PROFESSIONALS IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH AREAS. IN JUNE 2012, THE NIH'S NATIONAL CANCER INSTITUTE (NCI) NAMED THE UNIVERSITY OF KANSAS CANCER CENTER AN NCI-DESIGNATED CANCER CENTER. THE NCI CANCER CENTERS PROGRAM IS A PILLAR OF FEDERAL CANCER RESEARCH EFFORTS AND INTEGRAL TO THE NCI'S PROGRAMS FOR STUDYING, TREATING, AND PREVENTING CANCER. IN KUMC'S APPLICATION TO THE NCI CANCER CENTERS PROGRAM, $4 MILLION OF THE $48 MILLION IN GRANTS CITED IN THE APPLICATION WERE GRANTS THAT HAD BEEN AWARDED TO SIMR INVESTIGATORS. IN 2020, TWELVE SIMR RESEARCH PROGRAM LEADERS WERE MEMBERS OF THE UNIVERSITY OF KANSAS CANCER CENTER'S CANCER BIOLOGY RESEARCH PROGRAM, INCLUDING LINHENG LI, PHD, WHO SERVES AS CO-LEADER OF THE PROGRAM. IN 2020, SIMR RESEARCH PROGRAM LEADER LINHENG LI, PHD, CONTINUED A COLLABORATION WITH THE UNIVERSITY OF KANSAS CANCER CENTER AND CHILDREN'S MERCY HOSPITAL, KANSAS CITY, MO, TO INVESTIGATE APPROACHES TO TREAT LEUKEMIA. THIS RESEARCH FOCUSES ON TARGETING CANCER STEM CELLS TO HELP REDUCE THE RECURRENCE OF CANCER AFTER A PATIENT GOES INTO REMISSION. THE COLLABORATION BUILDS ON FOUNDATIONAL RESEARCH FROM THE LI LAB THAT HAS CHARACTERIZED CANCER STEM CELLS AT MOLECULAR AND CELLULAR LEVELS. THIS ONGOING RESEARCH COLLABORATION HAS GENERATED FINDINGS THAT HAVE BEEN REPORTED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING PERRY J ET AL, 2020. KUMC IS THE SPONSOR OF A RELATED CLINICAL RESEARCH STUDY, "LOW-DOSE DAUNORUBICIN IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA," WHICH IS DESIGNED TO ASSESS THE FEASIBILITY AND TOLERABILITY OF ADMINISTERING A LOW DOSE OF THE DRUG TO PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), AND TO OBTAIN PRELIMINARY DATA ON THE DRUG ENGAGING ITS TARGET. IN 2020, SIMR RESEARCH PROGRAM LEADER MICHAEL WASHBURN, PHD, CONTINUED A RESEARCH PROJECT IN COLLABORATION WITH ROY JENSEN, MD, DIRECTOR OF THE UNIVERSITY OF KANSAS CANCER CENTER. THE OVERALL AIM OF THIS RESEARCH EFFORT IS TO DETERMINE HOW CANCER THERAPEUTICS ACT ON PROTEIN NETWORKS IN CELLS AND TISSUES. JENSEN IS A WORLD-RENOWNED EXPERT ON BREAST CANCER AND HOLDS ADDITIONAL POSITIONS AS DIRECTOR, KANSAS MASONIC CANCER RESEARCH INSTITUTE, WILLIAM R. JEWELL DISTINGUISHED KANSAS MASONIC PROFESSOR, AND PROFESSOR OF PATHOLOGY AND LABORATORY MEDICINE, ANATOMY AND CELL BIOLOGY, CANCER BIOLOGY, AND MOLECULAR BIOSCIENCES AT KUMC. THE PROJECT AIMS TO FURTHER EXPLORE THE MECHANISM OF ACTION OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), WHICH IS USED AS CHEMOTHERAPY FOR CERTAIN LYMPHOMAS AND IS BEING EVALUATED IN CLINICAL TRIALS FOR OTHER CANCERS. RECENT REPORTS SUGGEST THAT SAHA HAS ADDITIONAL EFFECTS THAT INVOLVE PROTEIN NETWORKS MORE BROADLY, THUS SUGGESTING OTHER POSSIBLE MECHANISMS OF ACTION. RESULTS FROM THIS JOINT RESEARCH EFFORT MAY ENABLE THE FUTURE DEVELOPMENT OF MORE SPECIFIC AND EFFECTIVE HUMAN THERAPEUTICS. THIS PROJECT IS SUPPORTED IN PART BY A NIH GRANT FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES AND HAS GENERATED FINDINGS THAT HAVE BEEN REPORTED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING LEVY MJ ET AL, 2020, LIU ET AL, 2020, AND BANKS ET AL, 2020. IN 2020, SIMR SCIENTISTS ALSO COLLABORATED WITH RESEARCHERS AT EIGHTY-SEVEN NATIONAL AND SIXTY-FOUR INTERNATIONAL INSTITUTIONS INCLUDING DOZENS OF HOSPITALS, MEDICAL CENTERS, AND MEDICAL SCHOOLS. MANY OF THESE COLLABORATIONS RESULTED IN DISCOVERIES THAT MERITED PUBLICATION IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS AND/OR SUCCESSFULLY FUNDED GRANT AWARDS. SIMR PARTICIPATED IN COLLABORATIONS CONDUCTING RESEARCH IN CONJUNCTION WITH THE FOLLOWING US HOSPITALS, PURSUANT TO AN UNDERSTANDING TO MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH IN 2020: INSTITUTION LOCATION BRIGHAM AND WOMEN'S HOSPITAL BOSTON, MA CHILDREN'S MERCY HOSPITAL KANSAS CITY, MO CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER CINCINNATI, OH DANA-FARBER CANCER INSTITUTE BOSTON, MA DUKE UNIVERSITY MEDICAL CENTER DURHAM, NC GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES WASHINGTON, DC HARVARD MEDICAL SCHOOL BOSTON, MA JOHNS HOPKINS SCHOOL OF MEDICINE BALTIMORE, MD LE BONHEUR CHILDREN'S HOSPITAL MEMPHIS, TN MEMORIAL SLOAN KETTERING CANCER CENTER NEW YORK, NY NEW YORK UNIVERSITY LANGONE MEDICAL CENTER NEW YORK, NY SEATTLE CHILDREN'S HOSPITAL SEATTLE, WA SHRINER'S HOSPITALS FOR CHILDREN - NORTHERN CALIFORNIA SACRAMENTO, CA ST. JUDE CHILDREN'S RESEARCH HOSPITAL NASHVILLE, TN STANFORD UNIVERSITY SCHOOL OF MEDICINE STANFORD, CA UNIVERSITY OF CALIFORNIA LOS ANGELES DAVID GEFFEN SCHOOL OF MEDICINE LOS ANGELES, CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO, CA UNIVERSITY OF CINCINNATI MEDICAL CENTER CINCINNATI, OH UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS AURORA, CO UNIVERSITY OF KANSAS CANCER CENTER KANSAS CITY, KS UNIVERSITY OF KANSAS MEDICAL CENTER KANSAS CITY, KS UNIVERSITY OF MISSOURI-KANSAS CITY SCHOOL OF MEDICINE KANSAS CITY, MO UNIVERSITY OF PENNSYLVANIA PERELMAN SCHOOL OF MEDICINE PHILADELPHIA, PA UNIVERSITY OF PITTSBURGH CANCER INSTITUTE PITTSBURGH, PA UNIVERSITY OF ROCHESTER MEDICAL CENTER ROCHESTER, NY UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER MEMPHIS, TN UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON HOUSTON, TX UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON, TX UNIVERSITY OF VERMONT CANCER CENTER BURLINGTON, VT UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE CHARLOTTESVILLE, VA UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE, WA UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH MADISON, WI VANDERBILT UNIVERSITY MEDICAL CENTER NASHVILLE, TN WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ST.LOUIS, MO WEILL CORNELL SCHOOL OF MEDICINE NEW YORK, NY TO CARRY OUT THE RESEARCH DESCRIBED IN THE FOLLOWING EXAMPLES, SIMR AND HOSPITAL, MEDICAL CENTER, OR MEDICAL SCHOOL ENTERED INTO A COOPERATION AGREEMENT PURSUANT TO WHICH THEY AGREED TO ESTABLISH, DEVELOP, ADMINISTER, AND MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH, INCLUDING THROUGH SPECIFIC COOPERATIVE EFFORTS IN THE AREAS OF RESEARCH, SHARING OF INFORMATION, PURSUANT OF JOINT GRANTS, INTERACTION OF STAFF, ADJUNCT/JOINT APPOINTMENTS, AND SHARING OF FACILITIES. TO ASSURE THE SUCCESS OF THEIR COOPERATIVE RELATIONSHIP, EACH AGREED TO ENGAGE IN EFFECTIVE, COORDINATED, AND ONGOING PLANNING, OVERSIGHT, AND COMMUNICATION, AND TO COMMIT THE NECESSARY RESOURCES, BOTH HUMAN AND MONETARY, TO SUPPORT, FACILITATE, AND PROMOTE THE COOPERATION. JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS - THE LI LAB PERFORMED JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS WITH COLLABORATORS AT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA, OREGON HEALTH AND SCIENCE UNIVERSITY SCHOOL OF MEDICINE, STANFORD UNIVERSITY SCHOOL OF MEDICINE, AND UNIVERSITY OF PITTSBURGH CANCER INSTITUTE. INTESTINAL DISEASES RANGING FROM CROHN'S DISEASE TO COLITIS TO CANCER MAY BENEFIT FROM INTESTINAL STEM CELL THERAPIES. THIS RESEARCH ADVANCES THE UNDERSTANDING OF THE BIOLOGY OF STEM CELLS THAT RESIDE IN THE INTESTINE AND EXPLORES HOW THEY CAN BE USED TO TREAT AND CURE INTESTINAL DISEASES. THIS RESEARCH COLLABORATION IS SUPPORTED IN PART BY A NIH GRANT AWARDED BY THE NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES AND HAS GENERATED FINDINGS PUBLISHED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING KARMAKAR S ET AL, 2020. JOINT MEDICAL RESEARCH ON EYE DEVELOPMENT AND FUNCTION - THE XIE LAB PERFORMED JOINT MEDI

Return Reference

Explanation

PART I, LINE 4

STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") CONDUCTS MEDICAL RESEARCH IN CONJUNCTION WITH THE UNIVERSITY OF KANSAS (KU) AND ITS AFFILIATES, THE UNIVERSITY OF KANSAS HOSPITAL AUTHORITY AND THE UNIVERSITY OF KANSAS MEDICAL CENTER (KUMC), PURSUANT TO A WRITTEN MEMORANDUM OF UNDERSTANDING. KUMC IS THE ACADEMIC HEALTH SCIENCE CENTER OF THE LARGEST PUBLIC RESEARCH UNIVERSITY IN THE STATE OF KANSAS. KUMC OFFERS PROGRAMS AND SERVICES THAT FOCUS ON EDUCATION, RESEARCH, PATIENT CARE, AND COMMUNITY ENGAGEMENT. AS OF DECEMBER 31, 2020, FIVE KUMC STUDENTS HAVE RECEIVED MS DEGREES AND FORTY-SIX KUMC STUDENTS HAVE RECEIVED PHD DEGREES FOR THESIS WORK PERFORMED IN SIMR LABS. KUMC IS AFFILIATED WITH THE UNIVERSITY OF KANSAS HOSPITAL, A NONPROFIT INDEPENDENT HOSPITAL CO-LOCATED WITH THE MAIN KUMC CAMPUS IN KANSAS CITY, KS. IN 2020, TWENTY SIMR RESEARCH PROGRAM LEADERS WERE ADJUNCT FACULTY IN FOUR KUMC DEPARTMENTS. THESE APPOINTMENTS INCLUDED TWELVE FULL PROFESSORS, FOUR ASSOCIATE PROFESSORS, AND FOUR ASSISTANT PROFESSORS. IN 2020, FORTY-EIGHT OF SIMR'S FIFTY-NINE ORIGINAL RESEARCH PUBLICATIONS INCLUDED BOTH SIMR AND KUMC AFFILIATIONS. ABOUT A DOZEN KUMC STUDENTS PERFORMED PREDOCTORAL RESEARCH IN SIMR LABS IN 2020. SIMR IS ALSO A CONSORTIUM MEMBER OF THE UNIVERSITY OF KANSAS CANCER CENTER AT KUMC, A CANCER RESEARCH AND CARE PARTNERSHIP SPANNING TWO STATES AND INVOLVING COLLABORATION AMONG RESEARCHERS, PHYSICIANS, AND CANCER SUPPORT PROFESSIONALS IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH AREAS. IN JUNE 2012, THE NIH'S NATIONAL CANCER INSTITUTE (NCI) NAMED THE UNIVERSITY OF KANSAS CANCER CENTER AN NCI-DESIGNATED CANCER CENTER. THE NCI CANCER CENTERS PROGRAM IS A PILLAR OF FEDERAL CANCER RESEARCH EFFORTS AND INTEGRAL TO THE NCI'S PROGRAMS FOR STUDYING, TREATING, AND PREVENTING CANCER. IN KUMC'S APPLICATION TO THE NCI CANCER CENTERS PROGRAM, $4 MILLION OF THE $48 MILLION IN GRANTS CITED IN THE APPLICATION WERE GRANTS THAT HAD BEEN AWARDED TO SIMR INVESTIGATORS. IN 2020, TWELVE SIMR RESEARCH PROGRAM LEADERS WERE MEMBERS OF THE UNIVERSITY OF KANSAS CANCER CENTER'S CANCER BIOLOGY RESEARCH PROGRAM, INCLUDING LINHENG LI, PHD, WHO SERVES AS CO-LEADER OF THE PROGRAM. IN 2020, SIMR RESEARCH PROGRAM LEADER LINHENG LI, PHD, CONTINUED A COLLABORATION WITH THE UNIVERSITY OF KANSAS CANCER CENTER AND CHILDREN'S MERCY HOSPITAL, KANSAS CITY, MO, TO INVESTIGATE APPROACHES TO TREAT LEUKEMIA. THIS RESEARCH FOCUSES ON TARGETING CANCER STEM CELLS TO HELP REDUCE THE RECURRENCE OF CANCER AFTER A PATIENT GOES INTO REMISSION. THE COLLABORATION BUILDS ON FOUNDATIONAL RESEARCH FROM THE LI LAB THAT HAS CHARACTERIZED CANCER STEM CELLS AT MOLECULAR AND CELLULAR LEVELS. THIS ONGOING RESEARCH COLLABORATION HAS GENERATED FINDINGS THAT HAVE BEEN REPORTED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING PERRY J ET AL, 2020. KUMC IS THE SPONSOR OF A RELATED CLINICAL RESEARCH STUDY, "LOW-DOSE DAUNORUBICIN IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA," WHICH IS DESIGNED TO ASSESS THE FEASIBILITY AND TOLERABILITY OF ADMINISTERING A LOW DOSE OF THE DRUG TO PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), AND TO OBTAIN PRELIMINARY DATA ON THE DRUG ENGAGING ITS TARGET. IN 2020, SIMR RESEARCH PROGRAM LEADER MICHAEL WASHBURN, PHD, CONTINUED A RESEARCH PROJECT IN COLLABORATION WITH ROY JENSEN, MD, DIRECTOR OF THE UNIVERSITY OF KANSAS CANCER CENTER. THE OVERALL AIM OF THIS RESEARCH EFFORT IS TO DETERMINE HOW CANCER THERAPEUTICS ACT ON PROTEIN NETWORKS IN CELLS AND TISSUES. JENSEN IS A WORLD-RENOWNED EXPERT ON BREAST CANCER AND HOLDS ADDITIONAL POSITIONS AS DIRECTOR, KANSAS MASONIC CANCER RESEARCH INSTITUTE, WILLIAM R. JEWELL DISTINGUISHED KANSAS MASONIC PROFESSOR, AND PROFESSOR OF PATHOLOGY AND LABORATORY MEDICINE, ANATOMY AND CELL BIOLOGY, CANCER BIOLOGY, AND MOLECULAR BIOSCIENCES AT KUMC. THE PROJECT AIMS TO FURTHER EXPLORE THE MECHANISM OF ACTION OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), WHICH IS USED AS CHEMOTHERAPY FOR CERTAIN LYMPHOMAS AND IS BEING EVALUATED IN CLINICAL TRIALS FOR OTHER CANCERS. RECENT REPORTS SUGGEST THAT SAHA HAS ADDITIONAL EFFECTS THAT INVOLVE PROTEIN NETWORKS MORE BROADLY, THUS SUGGESTING OTHER POSSIBLE MECHANISMS OF ACTION. RESULTS FROM THIS JOINT RESEARCH EFFORT MAY ENABLE THE FUTURE DEVELOPMENT OF MORE SPECIFIC AND EFFECTIVE HUMAN THERAPEUTICS. THIS PROJECT IS SUPPORTED IN PART BY A NIH GRANT FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES AND HAS GENERATED FINDINGS THAT HAVE BEEN REPORTED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING LEVY MJ ET AL, 2020, LIU ET AL, 2020, AND BANKS ET AL, 2020. IN 2020, SIMR SCIENTISTS ALSO COLLABORATED WITH RESEARCHERS AT EIGHTY-SEVEN NATIONAL AND SIXTY-FOUR INTERNATIONAL INSTITUTIONS INCLUDING DOZENS OF HOSPITALS, MEDICAL CENTERS, AND MEDICAL SCHOOLS. MANY OF THESE COLLABORATIONS RESULTED IN DISCOVERIES THAT MERITED PUBLICATION IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS AND/OR SUCCESSFULLY FUNDED GRANT AWARDS. SIMR PARTICIPATED IN COLLABORATIONS CONDUCTING RESEARCH IN CONJUNCTION WITH THE FOLLOWING US HOSPITALS, PURSUANT TO AN UNDERSTANDING TO MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH IN 2020: INSTITUTION LOCATION BRIGHAM AND WOMEN'S HOSPITAL BOSTON, MA CHILDREN'S MERCY HOSPITAL KANSAS CITY, MO CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER CINCINNATI, OH DANA-FARBER CANCER INSTITUTE BOSTON, MA DUKE UNIVERSITY MEDICAL CENTER DURHAM, NC GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES WASHINGTON, DC HARVARD MEDICAL SCHOOL BOSTON, MA JOHNS HOPKINS SCHOOL OF MEDICINE BALTIMORE, MD LE BONHEUR CHILDREN'S HOSPITAL MEMPHIS, TN MEMORIAL SLOAN KETTERING CANCER CENTER NEW YORK, NY NEW YORK UNIVERSITY LANGONE MEDICAL CENTER NEW YORK, NY SEATTLE CHILDREN'S HOSPITAL SEATTLE, WA SHRINER'S HOSPITALS FOR CHILDREN - NORTHERN CALIFORNIA SACRAMENTO, CA ST. JUDE CHILDREN'S RESEARCH HOSPITAL NASHVILLE, TN STANFORD UNIVERSITY SCHOOL OF MEDICINE STANFORD, CA UNIVERSITY OF CALIFORNIA LOS ANGELES DAVID GEFFEN SCHOOL OF MEDICINE LOS ANGELES, CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO, CA UNIVERSITY OF CINCINNATI MEDICAL CENTER CINCINNATI, OH UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS AURORA, CO UNIVERSITY OF KANSAS CANCER CENTER KANSAS CITY, KS UNIVERSITY OF KANSAS MEDICAL CENTER KANSAS CITY, KS UNIVERSITY OF MISSOURI-KANSAS CITY SCHOOL OF MEDICINE KANSAS CITY, MO UNIVERSITY OF PENNSYLVANIA PERELMAN SCHOOL OF MEDICINE PHILADELPHIA, PA UNIVERSITY OF PITTSBURGH CANCER INSTITUTE PITTSBURGH, PA UNIVERSITY OF ROCHESTER MEDICAL CENTER ROCHESTER, NY UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER MEMPHIS, TN UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON HOUSTON, TX UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON, TX UNIVERSITY OF VERMONT CANCER CENTER BURLINGTON, VT UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE CHARLOTTESVILLE, VA UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE, WA UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH MADISON, WI VANDERBILT UNIVERSITY MEDICAL CENTER NASHVILLE, TN WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ST.LOUIS, MO WEILL CORNELL SCHOOL OF MEDICINE NEW YORK, NY TO CARRY OUT THE RESEARCH DESCRIBED IN THE FOLLOWING EXAMPLES, SIMR AND HOSPITAL, MEDICAL CENTER, OR MEDICAL SCHOOL ENTERED INTO A COOPERATION AGREEMENT PURSUANT TO WHICH THEY AGREED TO ESTABLISH, DEVELOP, ADMINISTER, AND MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH, INCLUDING THROUGH SPECIFIC COOPERATIVE EFFORTS IN THE AREAS OF RESEARCH, SHARING OF INFORMATION, PURSUANT OF JOINT GRANTS, INTERACTION OF STAFF, ADJUNCT/JOINT APPOINTMENTS, AND SHARING OF FACILITIES. TO ASSURE THE SUCCESS OF THEIR COOPERATIVE RELATIONSHIP, EACH AGREED TO ENGAGE IN EFFECTIVE, COORDINATED, AND ONGOING PLANNING, OVERSIGHT, AND COMMUNICATION, AND TO COMMIT THE NECESSARY RESOURCES, BOTH HUMAN AND MONETARY, TO SUPPORT, FACILITATE, AND PROMOTE THE COOPERATION. JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS - THE LI LAB PERFORMED JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS WITH COLLABORATORS AT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA, OREGON HEALTH AND SCIENCE UNIVERSITY SCHOOL OF MEDICINE, STANFORD UNIVERSITY SCHOOL OF MEDICINE, AND UNIVERSITY OF PITTSBURGH CANCER INSTITUTE. INTESTINAL DISEASES RANGING FROM CROHN'S DISEASE TO COLITIS TO CANCER MAY BENEFIT FROM INTESTINAL STEM CELL THERAPIES. THIS RESEARCH ADVANCES THE UNDERSTANDING OF THE BIOLOGY OF STEM CELLS THAT RESIDE IN THE INTESTINE AND EXPLORES HOW THEY CAN BE USED TO TREAT AND CURE INTESTINAL DISEASES. THIS RESEARCH COLLABORATION IS SUPPORTED IN PART BY A NIH GRANT AWARDED BY THE NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES AND HAS GENERATED FINDINGS PUBLISHED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING KARMAKAR S ET AL, 2020. JOINT MEDICAL RESEARCH ON EYE DEVELOPMENT AND FUNCTION - THE XIE LAB PERFORMED JOINT MEDI

Schedule A (Form 990 or 990-EZ) 2020

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990, 990-EZ,
or 990-PF)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2020

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling $5,000 or more (in money or other property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

Special Rules

For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990 or 990-EZ), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I, II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions exclusively for religious, charitable, etc., purposes, but no such contributions totaled more than $1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Don't complete any of the parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions totaling $5,000 or more during the year ......... Arrow Bullet

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ
or on its Form 990PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2020)

Schedule B (Form 990, 990-EZ, or 990-PF) (2020) Page 2

Name of organization STOWERS INSTITUTE FOR MEDICAL RESEARCH

Part I Contributors	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	,	$ RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2020)

Schedule B (Form 990, 990-EZ, or 990-PF) (2020)

Page 3

Name of organization STOWERS INSTITUTE FOR MEDICAL RESEARCH		Employer identification number 20-2993509

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
Schedule B (Form 990, 990-EZ, or 990-PF) (2020)

Schedule B (Form 990, 990-EZ, or 990-PF) (2020)

Page 4


Name of organization STOWERS INSTITUTE FOR MEDICAL RESEARCH			Employer identification number 20-2993509
Part III Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than $1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of $1,000 or less for the year. (Enter this information once. See instructions.) $ Use duplicate copies of Part III if additional space is needed.

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990, 990-EZ, or 990-PF) (2020)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
SchDMd Bullet

Attach to Form 990.
SchDMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2020

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate value of contributions to (during year)
3	Aggregate value of grants from (during year)
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization’s property, subject to the organization’s exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements ......................	2a
b	Total acreage restricted by conservation easements ....................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register ...	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the
tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ............

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .............................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenue included on Form 990, Part VIII, line 1 ......................... SchDMd Bullet

(ii)

Assets included in Form 990, Part X ............................... SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under FASB ASC 958 relating to these items:

Revenue included on Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2020

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?...

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No


b	If "Yes," explain the arrangement in Part XIII and complete the following table:		Amount
c	Beginning balance .............................	1c
d	Additions during the year ............................	1d
e	Distributions during the year ..........................	1e
f	Ending balance ................................	1f

Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ...

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ....

Part V

Endowment Funds.
Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

		(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back

1a	Beginning of year balance ....	206,378	120,721	550,240	626,653	39,191
b	Contributions ...	27,200	163,200	75,000	100,000	661,216
c	Net investment earnings, gains, and losses
d	Grants or scholarships ...
e	Other expenditures for facilities and programs ...	24,571	77,543	504,519	176,413	73,754
f	Administrative expenses ....
g	End of year balance ......	209,007	206,378	120,721	550,240	626,653

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

Permanent endowment SchDMd Bullet

Term endowment SchDMd Bullet

100.000 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) Unrelated organizations .......................

3a(i)

(ii) Related organizations .......................

3a(ii)

If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value

1a	Land .....	3,400,000		3,400,000
b	Buildings ....	233,552,194	122,042,783	111,509,411
c	Leasehold improvements	0	0	0
d	Equipment ....	96,601,719	80,937,679	15,664,040
e	Other .....	501,128	0	501,128
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..				131,074,579

Schedule D (Form 990) 2020

Page 3

Part VII

Investments - Other Securities.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives.........
(2) Closely-held equity interests........
(3)Other
(B)
(C)
(D)
(E)
(F)
(G)
(H)
(I)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)

Part VIII

Investments - Program Related. Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value

(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value
(1)ANNUITY REC. FROM AFFILIATE				80,888,105
(2)OTHER RECEIVABLES				231,622
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........				81,119,727

Part X

Other Liabilities.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability	(b) Book value
(1) Federal income taxes	0
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)	86,997,852
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Schedule D (Form 990) 2020

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......		1
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains (losses) on investments ....	2a
b	Donated services and use of facilities .........	2b
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d .....................		2e
3	Subtract line 2e from line 1..................		3
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a
b	Other (Describe in Part XIII.) ...........	4b
c	Add lines 4a and 4b....................		4c
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......		5

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........		1
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities .........	2a
b	Prior year adjustments ............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d....................		2e
3	Subtract line 2e from line 1...................		3
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a
b	Other (Describe in Part XIII.) ............	4b
c	Add lines 4a and 4b.....................		4c
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......		5

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference	Explanation
PART V, LINE 4:	THE ENDOWMENT IS FROM A SINGLE DONOR TO CONTRIBUTE FUNDING TOWARDS AN ESTABLISHED LECTURE SERIES PROGRAM WHERE SIMR HOSTS SCIENCE SPEAKERS FROM OTHER RESEARCH INSTITUTIONS AND UNIVERSITIES TO ENCOURAGE COLLABORATIVE SCIENCE OPPORTUNITIES WITH TOP SCIENTISTS FROM AROUND THE WORLD.
PART X, LINE 2:	FIN 48 FINANCIAL STATEMENT FOOTNOTE FROM THE CONSOLIDATED STATEMENTS OF STOWERS INSTITUTE FOR MEDICAL RESEARCH (THE INSTITUTE) IS AS FOLLOWS: THE INSTITUTE RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. RECOGNIZED INCOME TAX POSITIONS ARE MEASURED AT THE LARGEST AMOUNT THAT IS GREATER THAN 50% LIKELY OF BEING REALIZED.

Schedule D (Form 990) 2020

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
Graphic Arrow

Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
Graphic Arrow

Attach to Form 990.
Graphic Arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2020

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed on Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a? ....

Yes

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? .............

Yes

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ....................

Yes

Any related organization? .......................

If "Yes," on line 5a or 5b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ..................

Any related organization? ......................

If "Yes," on line 6a or 6b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported on Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III ..........................

If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2020

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
1DAVID A WELTE DIRECTOR/SECRETARY	(i) (ii)	0 ------------- 1,389,618	0 ------------- 0	0 ------------- 37,135	0 ------------- 42,750	0 ------------- 30,216	0 ------------- 1,499,719	0 ------------- 0
2RODERICK L STURGEON DIRECTOR/CFO	(i) (ii)	0 ------------- 1,621,741	0 ------------- 0	0 ------------- 104,113	0 ------------- 42,750	0 ------------- 23,768	0 ------------- 1,792,372	0 ------------- 0
3DAVID M CHAO DIR/PRESIDENT/CEO TIL 10/2020	(i) (ii)	846,761 ------------- 263,521	0 ------------- 0	0 ------------- 9,921	42,750 ------------- 0	1,283 ------------- 257	890,794 ------------- 273,699	0 ------------- 0
4ROBERT E KRUMLAUF SCIENTIFIC DIRECTOR EMERITUS	(i) (ii)	304,215 ------------- 0	0 ------------- 0	252,462 ------------- 0	42,750 ------------- 0	22,214 ------------- 0	621,641 ------------- 0	0 ------------- 0
5RICHARD W BROWN DIRECTOR/CHAIR	(i) (ii)	0 ------------- 2,554,058	0 ------------- 0	0 ------------- 27,281	0 ------------- 42,750	0 ------------- 20,944	0 ------------- 2,645,033	0 ------------- 0
6ALEJANDRO SANCHEZ ALVARADO DIR/CHIEF SCIENTIFIC OFFICER	(i) (ii)	104,688 ------------- 0	0 ------------- 0	49,110 ------------- 0	15,703 ------------- 0	0 ------------- 0	169,501 ------------- 0	0 ------------- 0
7BRENT KREIDER CHIEF OPERATING OFFICER	(i) (ii)	0 ------------- 589,996	0 ------------- 0	0 ------------- 9,086	0 ------------- 42,750	0 ------------- 26,439	0 ------------- 668,271	0 ------------- 0
8JOAN W CONAWAY INVESTIGATOR	(i) (ii)	325,715 ------------- 0	0 ------------- 0	3,564 ------------- 0	42,750 ------------- 0	20,972 ------------- 0	393,001 ------------- 0	0 ------------- 0
9JERRY L WORKMAN INVESTIGATOR	(i) (ii)	368,202 ------------- 0	0 ------------- 0	3,564 ------------- 0	42,750 ------------- 0	12,697 ------------- 0	427,213 ------------- 0	0 ------------- 0
10R SCOTT HAWLEY INVESTIGATOR	(i) (ii)	366,462 ------------- 0	0 ------------- 0	4,191 ------------- 0	42,750 ------------- 0	21,021 ------------- 0	434,424 ------------- 0	0 ------------- 0
11MICHAEL P WASHBURN INVESTIGATOR	(i) (ii)	126,389 ------------- 0	0 ------------- 0	431,379 ------------- 0	19,169 ------------- 0	8,338 ------------- 0	585,275 ------------- 0	0 ------------- 0
12CHARLES GERMAN DIRECTOR AS OF 10/29/2020	(i) (ii)	0 ------------- 634,899	0 ------------- 0	0 ------------- 17,369	0 ------------- 42,750	0 ------------- 16,642	0 ------------- 711,660	0 ------------- 0

Schedule J (Form 990) 2020

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference

Explanation

PART I, LINE 4A

SIMR ENTERED A SEVERANCE COMPENSATION AGREEMENT AS OF JULY 3, 2020 WITH MICHAEL WASHBURN, AS PART OF A TERMINATION PROGRAM UNDER WHICH THE WASHBURN LABORATORY AT SIMR WAS CLOSED. THE TERMINATION PROGRAM RESULTED FROM SIMR'S BUSINESS DECISION TO DISCONTINUE THE INVESTIGATIVE PROTEOMICS WORK OF THAT LABORATORY. UNDER THE AGREEMENT, DR. WASHBURN WAS PAID $337,032 (LESS TAXES AND WITHHOLDING) IN SEVERANCE AS PAYROLL, AND $93,724 AS A LUMP SUM BENEFITS PAYMENT REPORTED ON A FORM 1099. THE TERMS AND CONDITIONS OF THE AGREEMENT REQUIRED THE LABORATORY TO RETURN ALL PROPERTY AND TO PROVIDE AN INVENTORY OF ALL MATERIALS AND REAGENTS. THE AGREEMENT ALSO INCLUDED STANDARD RELEASES, AND IMPOSED CONFIDENTIALITY AND NON-DISPARAGEMENT OBLIGATIONS ON DR. WASHBURN.

PART I, LINE 5A:

SIMR MADE A PAYMENT OF $247,518 TO ROBERT E. KRUMLAUF, SCIENTIFIC DIRECTOR. THIS PAYMENT REPRESENTS THE PORTION OF THE NET ROYALTIES RECEIVED BY SIMR FOR LICENSED SCIENTIFIC DISCOVERY TECHNOLOGY THAT IS PAYABLE TO ROBERT E. KRUMLAUF, PH.D., FOR HIS PARTICIPATION IN THE DISCOVERY.

Schedule J (Form 990) 2020

Additional Data

Software ID:
Software Version:

- TIN:

Schedule L
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Transactions with Interested Persons

Complete if the organization answered "Yes" on Form 990, Part IV, lines 25a, 25b, 26, 27, 28a, 28b, or 28c, or Form 990-EZ, Part V, line 38a or 40b.
MediumBullet

Attach to Form 990 or Form 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2020

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Excess Benefit Transactions (section 501(c)(3), section 501(c)(4), and section 501(c)(29) organizations only).
Complete if the organization answered "Yes" on Form 990, Part IV, line 25a or 25b, or Form 990-EZ, Part V, line 40b.

1(a) Name of disqualified person	(c) Description of transaction	(d) Corrected?
1(a) Name of disqualified person	(c) Description of transaction	Yes	No

Enter the amount of tax incurred by the organization managers or disqualified persons during the year under section 4958. ........................... Bullet Image

Enter the amount of tax, if any, on line 2, above, reimbursed by the organization ........ Bullet Image

Part II

Loans to and/or From Interested Persons.
Complete if the organization answered "Yes" on Form 990-EZ, Part V, line 38a, or Form 990, Part IV, line 26; or if the organization reported an amount on Form 990, Part X, line 5, 6, or 22

(a) Name of interested person	(b) Relationship with organization	(c) Purpose of loan	(d) Loan to or from the organization?		(e) Original principal amount	(f) Balance due	(g) In default?		(h) Approved by board or committee?		(i) Written agreement?
(a) Name of interested person	(b) Relationship with organization	(c) Purpose of loan	To	From	(e) Original principal amount	(f) Balance due	Yes	No	Yes	No	Yes	No






Total ............... $

Part III

Grants or Assistance Benefiting Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 27.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of assistance	(d) Type of assistance	(e) Purpose of assistance

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 50056A

Schedule L (Form 990 or 990-EZ) 2020

Page 2

Part IV

Business Transactions Involving Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 28a, 28b, or 28c.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of transaction	(d) Description of transaction	(e) Sharing of organization's revenues?
(a) Name of interested person		(c) Amount of transaction	(d) Description of transaction	Yes	No
(1) JULIA ZEITLINGER PHD	SEE PART V	265,093	EMPLOYEE OF SIMR		No
(2) LEANNE WIEDEMANN PHD	SEE PART V	265,771	EMPLOYEE OF SIMR		No
(3) TATJANA PIOTROWSKI PHD	SEE PART V	250,654	EMPLOYEE OF SIMR		No

Part V

Supplemental Information
Provide additional information for responses to questions on Schedule L (see instructions).

Return Reference

Explanation

PART IV, LINES (1) , (2) & (3):

JULIA ZEITLINGER, PH.D, IS THE SPOUSE OF DAVID M. CHAO, PRESIDENT OF SIMR THROUGH 10/10/2020. MS. ZEITLINGER IS A INVESTIGATOR AT SIMR. MS. ZEITLINGER'S PREVIOUS EMPLOYMENT BEFORE SIMR WAS WITH THE WHITEHEAD INSTITUTE FOR MEDICAL RESEARCH WHERE SHE WAS THE RECIPIENT OF A PREDOCTORAL FELLOWSHIP FROM THE HUMAN FRONTIER SCIENCE PROGRAM. LEANNE WIEDMANN, PH.D, IS THE SPOUSE OF ROBERT KRUMLAUF, SCIENTIFIC DIRECTOR EMERITUS OF SIMR. MS. WIEDEMANN PERFORMS INDEPENDENT SCIENCE RESEARCH AT SIMR AND IS CONCURRENTLY A PROFESSOR AT THE UNIVERSITY OF KANSAS MEDICAL CENTER IN THE DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE. TATJANA PIOTROWSKI, PH.D, IS THE SPOUSE OF ALEJANDRO SANCHEZ ALVARADO, CHIEF SCIENTIFIC OFFICER OF SIMR. MS. PIOTROWSKI IS AN INVESTIGATOR AT SIMR. HER PREVIOUS EMPLOYMENT BEFORE SIMR WAS WITH THE UNIVERSITY OF UTAH'S SCHOOL OF MEDICINE WHERE SHE WAS AN ASSOCIATE PROFESSOR IN THE DEPARTMENT OF NEUROBIOLOGY AND ANATOMY.

Schedule L (Form 990 or 990-EZ) 2020

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.
Right pointing arrow large image

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2020

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	3	61,100,000	FAIR MARKET VALUE
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( )
26 Other ( )
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? ...................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

If "Yes," describe in Part II.

If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2020)

Page 2

Part IISupplemental Information. Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Return Reference	Explanation
PART I, COLUMN B:	THE AMOUNTS SHOWN IN PART I, COLUMN (B) FOR "NUMBER OF CONTRIBUTIONS" REPRESENTS THE TOTAL NUMBER OF CONTRIBUTIONS AND NOT NECESSARILY THE TOTAL NUMBER OF ITEMS CONTRIBUTED.

Schedule M (Form 990) (2020)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2020

Open to Public
Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Return Reference	Explanation
PART III, LINE 1:	THE STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") PERFORMS MEDICAL RESEARCH IN THE PUBLIC INTEREST WITH THE GOAL OF EXPANDING THE UNDERSTANDING OF FUNDAMENTAL PROCESSES IN LIVING CELLS AND IMPROVING LIFE'S QUALITY THROUGH INNOVATIVE APPROACHES TO THE CAUSES, TREATMENT, AND PREVENTION OF DISEASE. PART III, LINE 4: SIMR'S ACCOMPLISHMENTS ARE DESCRIBED AT THE END OF SCHEDULE O. PART VI, LINE 2: VIRGINIA G. STOWERS, JONATHAN THOMAS, RICHARD W. BROWN, DAVID A. WELTE, DAVID M. CHAO, CHARLES GERMAN, ALBERZINE FREEMAN, AND ALEJANDRO SANCHEZ ALVARADO, ALL DIRECTORS OF SIMR, HAVE A BUSINESS RELATIONSHIP. JONATHAN THOMAS, RICHARD W. BROWN, DAVID A. WELTE, DAVID M. CHAO, CHARLES GERMAN, RODERICK L. STURGEON, AND ALBERZINE FREEMAN, DIRECTORS OF SIMR, AND BRENT KREIDER, OFFICER OF SIMR, HAVE A BUSINESS RELATIONSHIP. DAVID A. WELTE, RICHARD W. BROWN, CHARLES GERMAN, AND RODERICK L. STURGEON, DIRECTORS OF SIMR, AND BRENT KREIDER, OFFICER OF SIMR, HAVE A BUSINESS RELATIONSHIP. PART VI, LINE 11B: THE DATA AND INFORMATION NECESSARY TO PREPARE SIMR'S FORM 990 WAS COMPILED BY SIMR'S ACCOUNTING DEPARTMENT AND THEN REVIEWED BY THE INSTITUTE'S TAX ATTORNEY AT BRYAN CAVE LEIGHTON PAISNER, LLP. PRICEWATERHOUSECOOPERS ("PWC"), THE INSTITUTE'S EXTERNAL TAX PREPARERS, USED THIS INFORMATION TO PREPARE THE FORM 990. THE COMPLETED FORM 990, INCLUDING REQUIRED SCHEDULES, IS REVIEWED BY THE OFFICERS OF SIMR BEFORE IT IS FILED WITH THE IRS. AFTER THE PREPARATION AND REVIEW PROCESS DESCRIBED ABOVE, THE FORM 990, INCLUDING REQUIRED SCHEDULES, IS PROVIDED TO EACH VOTING MEMBER OF THE ORGANIZATION'S BOARD BEFORE IT IS FILED WITH THE IRS. PART VI, LINE 12C: SIMR HAS ADOPTED A "CONFLICTS OF INTEREST AND DIRECTOR INDEPENDENCE POLICY". EACH DIRECTOR, OFFICER, AND ALL OTHER PERSONS IN A POSITION TO EXERCISE SUBSTANTIAL INFLUENCE OVER DECISIONS OF SIMR ARE REQUIRED TO ANNUALLY COMPLETE AND SIGN A DISCLOSURE STATEMENT THAT IS PART OF THE POLICY. A COVERED PERSON MUST ALSO DISCLOSE THE EXISTENCE OF A POTENTIAL CONFLICT AND ALL MATERIAL FACTS TO THE GOVERNING BOARD AS SOON AS THE PERSON HAS KNOWLEDGE THAT A POTENTIAL CONFLICT MIGHT EXIST. SIMR CONDUCTS PERIODIC AND ADHOC REVIEWS OF TRANSACTIONS AND AGREEMENTS TO ENSURE THAT IT ENGAGES ONLY IN ACTIVITIES THAT ARE CONSISTENT WITH ITS TAX-EXEMPT PURPOSE. PART VI, LINE 15A: THE COMPENSATION FOR DAVID CHAO, THE PRESIDENT AND CEO OF SIMR THROUGH 10/10/2020, WAS ESTABLISHED PURSUANT TO THE PROCEDURES OF TREAS. REG. SECTION 53.4958-6, INCLUDING (1) REVIEW AND APPROVAL BY SIMR'S COMPENSATION COMMITTEE COMPRISED OF INDEPENDENT PERSONS, (2) RELYING ON COMPARABILITY DATA, INCLUDING DATA PREPARED BY A NATIONALLY KNOWN COMPENSATION CONSULTANT REGARDING COMPARABLE SALARY AND BENEFITS FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS, AND (3) CONTEMPORANEOUS DOCUMENTATION AND RECORD KEEPING OF THE DELIBERATION AND DECISIONS REGARDING THE COMPENSATION ARRANGEMENT. THIS PROCESS WAS LAST UNDERTAKEN IN 2020. PART VI, LINE 19: SIMR'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. PART VII, SECTION A, COLUMN B: DAVID M. CHAO, OFFICER OF SIMR THROUGH 10/10/2020, PERFORMED SUPPORT SERVICES FOR ONE OR MORE OF THE RELATED ORGANIZATIONS DISCLOSED IN SCHEDULE R. THESE SERVICES WERE PERFORMED IN HIS ROLE AS A SIMR EMPLOYEE AND SIMR IS REIMBURSED BY THE RELATED ORGANIZATIONS. PART VII, SECTION B: SIMR RECEIVES INVESTMENT MANAGEMENT SERVICES FROM AMERICAN CENTURY INVESTMENTS ("ACI"). ACI IS A WHOLLY OWNED SUBSIDIARY OF AMERICAN CENTURY COMPANIES, INC. ("ACCI"). IN SELECTING ACI TO MANAGE ITS LIQUID INVESTMENTS, SIMR NOT ONLY CHOSE A HIGH QUALITY MUTUAL FUND COMPANY WITH AN OUTSTANDING TRACK RECORD, BUT ALSO PLACED ITS LIQUID INVESTMENTS IN A COMPANY IN WHICH IT OWNS STOCK AND RECEIVES DIVIDENDS. SIMR PAYS ACI THE SAME ADMINISTRATIVE FEES FOR THESE SERVICES AS ANY ARMS-LENGTH INVESTOR. THOSE INVESTMENT FEES FOR A SHARED INVESTMENT POOL ARE PAID BY ITS SUPPORTING ORGANIZATION, STOWERS RESOURCE MANAGEMENT. PART XI, LINE 9: OTHER CHANGES IN NET ASSETS INCLUDE THE FOLLOWING: CHANGE IN ANNUITY RECEIVABLE, NET ($208,120)
PART III, LINE 4A:	2020 PROGRAM SERVICE ACCOMPLISHMENTS THE STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") IS A PRIVATE, NONPROFIT MEDICAL RESEARCH ORGANIZATION. SIMR WAS FOUNDED IN 1994 BY JIM AND VIRGINIA STOWERS, WHO EACH SURVIVED A BOUT WITH CANCER AND SUBSEQUENTLY DEDICATED THEIR FORTUNE TO SUPPORTING BASIC RESEARCH IN CELL AND MOLECULAR BIOLOGY THAT WILL PROVIDE LONG-TERM SOLUTIONS TO HUMAN DISEASES. SIMR CONDUCTS BASIC BIOMEDICAL RESEARCH IN THE PUBLIC INTEREST THAT WILL ULTIMATELY PROVIDE A GREATER UNDERSTANDING OF THE GENES AND PROTEINS THAT CONTROL HOW CELLS IN OUR BODIES MULTIPLY, FORM TISSUES, AND DIE. STUDYING THE BASIC BIOLOGY OF CELLS ENABLES SCIENTISTS TO DISCOVER HOW GENES CAUSE MANY DISEASES, INCLUDING CANCER, BIRTH DEFECTS, AND DEMENTIA. HISTORY HAS SHOWN THAT BASIC MEDICAL RESEARCH IS OFTEN A KEY FIRST STEP IN THE DEVELOPMENT OF NEW TREATMENTS, CURES, AND PREVENTIONS FOR MANY HUMAN DISEASES. 2020 NOTABLE RESEARCH RESULTS IN 2020, SIMR RESEARCH TEAMS MADE DISCOVERIES MERITING PUBLICATION IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS - FIFTY-NINE ORIGINAL RESEARCH PAPERS IN ALL. SIMR RESEARCH TEAMS ALSO PRODUCED TWENTY-NINE OTHER PUBLICATIONS INCLUDING REVIEWS, COMMENTARIES, BOOK CHAPTERS, AND BOOKS. SOME OF THE HIGHLIGHTS AMONG THESE PAPERS AND OTHER ADVANCES INVOLVING STOWERS RESEARCH INCLUDE THE FOLLOWING: THE SI LAB CHARACTERIZED THE STRUCTURE OF A PROTEIN CALLED ORB2, WHICH IS NEEDED FOR LONG-TERM MEMORY FORMATION AND PERSISTENCE, AT ATOMIC-LEVEL RESOLUTION. PREVIOUS WORK BY THE SI LAB AND OTHERS HAD INDICATED THAT ORB2 MAY BE ABLE TO ADOPT THE SHAPE OF AN AMYLOID AS PART OF ITS NORMAL AND NECESSARY FUNCTION. HOWEVER, IT HAD NOT BEEN ESTABLISHED THAT ORB2 EXISTS IN THE BRAIN AS A BONA FIDE AMYLOID, AS ITS STRUCTURE WAS NOT PREVIOUSLY KNOWN. THE SI LAB PURIFIED ORB2 FROM ITS NATIVE SOURCE (THE BRAINS OF MILLIONS OF FRUIT FLIES) AND DEMONSTRATED THAT IT DOES INDEED EXIST AS A FUNCTIONAL AMYLOID WITHIN THE BRAIN. THIS STUDY MARKS THE FIRST TIME AN AMYLOID WITH A KNOWN BIOLOGICAL FUNCTION HAS EVER BEEN PURIFIED AND DESCRIBED STRUCTURALLY FROM THE BRAIN. THESE FINDINGS RAISE TWO INTERESTING POSSIBILITIES THAT WILL BE FURTHER PURSUED IN THE SI LAB-THE POSSIBILITY THAT SUCH A FUNCTIONING NEURONAL AMYLOID ALSO EXISTS IN HUMANS, AND THE POSSIBILITY THAT OTHER PROTEINS, KNOWN TO HAVE SPECIFIC FUNCTIONS, ARE CAPABLE OF ACHIEVING AMYLOID STATES TO ACHIEVE ALTERNATE FUNCTIONS. THIS WORK WAS PUBLISHED ONLINE MARCH 13, 2020, IN SCIENCE. THE WASHBURN LAB COMBINED SEVERAL PROTEOMICS TECHNOLOGIES TO STUDY PROTEIN NETWORKS AND OBTAIN DETAILED INFORMATION ABOUT THE SPATIAL ARRANGEMENT OF NEIGHBORING SURFACES WITHIN MULTI-PROTEIN COMPLEXES. IN PARTICULAR, THE RESEARCHERS FOCUSED ON SIN3/HDAC, A LARGE MULTI-PROTEIN COMPLEX THAT IS NORMALLY RESPONSIBLE FOR "TURNING OFF" A SPECIFIC SET OF GENES. WHEN ITS MAIN SCAFFOLD IS MUTATED, THE COMPLEX IS ALSO IMPLICATED IN CANCER BIOLOGY, AND IS TARGETED FOR TREATMENT OF MANY HUMAN CANCERS, INCLUDING TRIPLE NEGATIVE BREAST CANCER AND PANCREATIC CANCER. ALTHOUGH SIN3/HDAC HAS BEEN WELL STUDIED AND ITS COMPONENT SUBUNITS HAVE BEEN IDENTIFIED, GETTING A CLEAR PICTURE OF HOW THE SUBUNITS ASSEMBLE HAS BEEN DIFFICULT. THE RESEARCHERS COMBINED THREE EXISTING APPROACHES-AFFINITY TAG PROTEIN PURIFICATION, CHEMICAL CROSSLINKING WITH HIGH RESOLUTION MASS SPECTROMETRY, AND COMPUTATIONAL MOLECULAR MODELING WITH PROTEIN DOCKING-TO PINPOINT SPECIFIC SURFACES, WITHIN THE INTACT PROTEIN COMPLEX, THAT ARE IN VERY CLOSE PROXIMITY WITH EACH OTHER. IN TOTAL, THEY IDENTIFIED 66 INTER-PROTEIN CROSSLINKS (BETWEEN TWO DIFFERENT PROTEINS) AND 63 SELF-CROSSLINKS (WITHIN THE SAME PROTEIN) FOR 13 SIN3/HDAC SUBUNITS. MORE GENERALLY, USING THE COMBINED TECHNOLOGIES ALLOWS RESEARCHERS TO PINPOINT INTERACTING SURFACES IN VIRTUALLY ANY PROTEIN COMPLEX, OBTAINED FROM ANY SOURCE. THIS STUDY WAS PUBLISHED ONLINE APRIL 14, 2020, IN CELL REPORTS. THE LI LAB REPORTED A PROMISING NEW STRATEGY TO OVERCOME DRUG RESISTANCE IN LEUKEMIA, USING TARGETED DOSES OF THE WIDELY USED CHEMOTHERAPY DRUG DOXORUBICIN. THE FINDINGS WERE THE RESULT OF A DECADE-SPANNING COLLABORATIVE EFFORT AMONG RESEARCHERS AT THE STOWERS INSTITUTE FOR MEDICAL RESEARCH, CHILDREN'S MERCY KANSAS CITY, THE UNIVERSITY OF KANSAS CANCER CENTER, AND OTHER INSTITUTIONS, EVOLVING FROM STUDIES IN THE LI LAB. THE RESEARCHERS FOUND THAT LOW DOSES OF DOXORUBICIN, A STANDARD TREATMENT FOR SEVERAL TYPES OF CANCER INCLUDING LEUKEMIA, INHIBITS TWO MOLECULAR PATHWAYS-WNT/BETA-CATENIN AND PI3K/AKT-WHICH WORK CLOSELY TOGETHER TO PROMOTE TUMOR GROWTH AND RESISTANCE TO THERAPY. THE TEAM ALSO FOUND THAT LOW-DOSE BUT NOT HIGH-DOSE DOXORUBICIN ACTIVATED ANTICANCER IMMUNITY AGAINST THERAPY-RESISTANT LEUKEMIA STEM CELLS, AN UNEXPECTED AND NOVEL DISCOVERY. THE RESEARCH HOLDS PROMISE AS A MORE EFFECTIVE STRATEGY TO OVERCOME CANCER THERAPY RESISTANCE AND STIMULATE IMMUNITY THAT CAN BE USED IN COMBINATION WITH OTHER CANCER THERAPIES INCLUDING CHEMOTHERAPY, RADIATION, AND IMMUNOTHERAPY FOR PATIENTS WITH LEUKEMIA AND OTHER TYPES OF CANCER. LOW-DOSE DOXORUBICIN ALSO AVOIDS THE HARSH SIDE EFFECTS OF HIGH-DOSE DOXORUBICIN, POTENTIALLY OFFERING PATIENTS A BETTER QUALITY OF LIFE. THE FINDINGS WERE PUBLISHED ONLINE APRIL 20, 2020, IN NATURE CELL BIOLOGY. THE GERTON LAB DESCRIBED A DETAILED STUDY OF THE PLACENTAS OF MOUSE MODELS OF CORNELIA DE LANGE SYNDROME. PEOPLE WITH THIS RARE GENETIC DISORDER OFTEN HARBOR MUTATIONS IN COHESINS, RING-LIKE PROTEINS THAT HELP DNA ORGANIZE AND REPAIR ITSELF. THE RESEARCHERS DISCOVERED THAT THE CORNELIA DE LANGE MOUSE MODEL PLACENTAS ACCUMULATED DAMAGE TO THEIR DNA, ENTERED A PERMANENT GROWTH-ARRESTED STATE KNOWN AS SENESCENCE, AND CHURNED OUT PRO-INFLAMMATORY CYTOKINES THAT AFFECTED THE GROWTH OF THE EMBRYONIC MICE. THESE FINDINGS HAVE IMPORTANT IMPLICATIONS FOR UNDERSTANDING THE CRUCIAL ROLE THAT THE PLACENTA PLAYS IN MAMMALIAN DEVELOPMENT AND SUGGEST THAT TARGETING CYTOKINE SIGNALING MAY BE A WAY TO PROTECT THE HEALTH OF THE PLACENTA AND PROMOTE HEALTHY PREGNANCIES. THE STUDY WAS PUBLISHED ON JUNE 16, 2020, IN DEVELOPMENTAL CELL. THE BAZZINI LAB USED THE GENE-EDITING TOOL CRISPR TO TARGET GENE MESSAGES IN ANIMAL EMBRYOS TO GAIN A BETTER UNDERSTANDING OF THE GENETIC PROGRAMS THAT DIRECT EARLY STAGES OF VERTEBRATE DEVELOPMENT. THE RESEARCHERS AND THEIR COLLABORATORS SHOWED THAT THE TECHNOLOGY, CALLED CRISPR-CAS13, IS ABLE TO TARGET RNA-DNA'S CHEMICAL COUSIN THAT CARRIES MESSAGES NEEDED TO CONSTRUCT PROTEINS-IN ANIMAL EMBRYOS IN A SPECIFIC AND SYSTEMATIC MANNER, ALLOWING RESEARCHERS TO STUDY THE ROLE OF RNA IN THE EARLIEST HOURS OF DEVELOPMENT. THE RESEARCHERS SHOW THAT THE CRISPR-CAS13 METHOD IS EFFECTIVE IN ZEBRAFISH, KILLIFISH, MEDAKA, AND MOUSE EMBRYOS, AND THUS COULD BE USED TO EXPLORE EARLY DEVELOPMENTAL GENETIC PROGRAMS IN A BROAD RANGE OF ANIMAL SPECIES. THE STUDY WAS PUBLISHED ONLINE AUGUST 7, 2020, IN DEVELOPMENTAL CELL.
THE ZANDERS LAB UNCOVERED A STRATEGY THAT THE S. POMBE FISSION YEAST	GENOME CAN USE TO MINIMIZE SOME OF THE WORST EFFECTS CONFERRED BY PARASITIC GENE ELEMENTS KNOWN AS MEIOTIC DRIVERS. THE MEIOTIC DRIVERS ANALYZED IN THE STUDY HAVE THE ABILITY TO SHORT-CIRCUIT THE CONVENTIONAL LAW OF MENDELIAN SEGREGATION, WHICH USUALLY ENSURES THAT EACH GAMETE (REPRODUCTIVE CELL) RECEIVES ONE OF TWO COPIES OF EACH CHROMOSOME FROM THE PARENT CELL WITH EQUAL TRANSMISSION. MEIOTIC DRIVERS INSTEAD CAN "POISON" GAMETES THAT DO NOT CONTAIN THEIR GENETIC SEQUENCE, THEREBY SWINGING THE TRANSMISSION RATE IN THEIR FAVOR. AS A WAY OF ENABLING THE SURVIVAL OF SOME GAMETES THAT WOULD OTHERWISE DIE, THE S. POMBE GENOME CAN EMPLOY VARIANTS OF OTHER GENES TO CREATE A SITUATION THAT "PROTECTS" THEM, EVEN IF IT COMES AT A COST TO FITNESS. FOR EXAMPLE, A MUTATION IN REC12, A GENE RESPONSIBLE FOR PROPER CHROMOSOME SEGREGATION, LED TO GAMETES HAVING EXTRA CHROMOSOMES. WHILE EXTRA CHROMOSOMES ARE USUALLY UNDESIRABLE, IN THIS SCENARIO THEY ENABLED MORE GAMETES TO SURVIVE. THIS SURPRISING INSIGHT INTO MEIOTIC DRIVERS AND HOW THEY CAN BE SUPPRESSED COULD HELP RESEARCHERS BETTER UNDERSTAND THE FORCES THAT SHAPE THE EVOLUTION OF GAMETE FORMATION, AS WELL AS THOSE UNDERLYING HUMAN INFERTILITY. THIS RESEARCH WAS PUBLISHED ONLINE AUGUST 13, 2020, IN ELIFE. THE SNCHEZ ALVARADO LAB PUBLISHED A STUDY RELATED TO THE FUNDAMENTAL BIOLOGICAL QUESTION OF WHY SOME VERTEBRATE ANIMALS REGENERATE EXTENSIVELY WHILE OTHERS, SUCH AS MAMMALS, DO NOT. THE RESEARCHERS COMPARED THE REGENERATION PROCESS IN TWO SPECIES OF BONY FISH, ZEBRAFISH AND AFRICAN KILLIFISH, TO IDENTIFY SIMILARITIES AND DIFFERENCES IN THE GENOMIC RESPONSES UNDERLYING THE PROCESS. THE RESEARCHERS FOUND BOTH SPECIES-SPECIFIC AND EVOLUTIONARILY CONSERVED RESPONSES. THE CONSERVED RESPONSES REVEALED THE PRESENCE OF PARTICULAR DNA SEQUENCES CALLED REGENERATION-RESPONSIVE ENHANCERS (RRES) THAT ARE ALSO PRESENT IN MAMMALIAN GENOMES. SOME RRES APPEAR TO HAVE BEEN REPURPOSED DURING EVOLUTION, RESULTING IN A LOSS OF REGENERATIVE CAPACITY IN SOME SPECIES. THIS RESEARCH HELPS IDENTIFY MECHANISMS UNDERPINNING REGENERATIVE CAPACITY AND FURTHERS OUR UNDERSTANDING OF THE LONG-STANDING PROBLEM OF WHY SOME SPECIES CAN REGENERATE MISSING BODY PARTS AFTER AMPUTATION WHEREAS OTHERS CANNOT. THIS WORK WAS PUBLISHED ONLINE SEPTEMBER 4, 2020, IN SCIENCE. THE KRUMLAUF LAB IDENTIFIED TINY DIFFERENCES IN A KEY PROTEIN SEQUENCE THAT CAN HAVE AN IMPORTANT IMPACT ON HOW SPECIES EVOLVE. THE BREAKTHROUGH DISCOVERY SHEDS LIGHT ON THE EVOLUTION OF THE GENE REGULATORY NETWORKS THAT DRIVE DIVERSITY AMONG ORGANISMS. THE RESEARCHERS USED MODERN GENE EDITING TECHNOLOGIES TO REPLACE THE LABIAL HOX GENE IN THE FRUIT FLY WITH THE THREE RELATED GENES IN THE MOUSE-HOXA1, B1, AND D1. THEY FOUND REPLACING LABIAL FUNCTION WITH HOXA1 IN FRUIT FLIES RESTORES ITS ORIGINAL FUNCTION, BUT B1 AND D1 DO NOT, SUGGESTING THAT A1 RETAINS AN ANCESTRAL FUNCTION THAT HAS SURVIVED 600 MILLION YEARS OF EVOLUTION, WHILE B1 AND D1 HAVE DIVERGED. THE RESEARCHERS PINPOINTED A SIX AMINO ACID SEQUENCE CRITICAL FOR THE ANCESTRAL FUNCTION OF A1, WHICH IS IMPORTANT FOR MODULATING INTERACTIONS WITH OTHER PROTEINS. THE WORK PAVES THE WAY FOR ADDITIONAL STUDIES ON THE EVOLUTION OF PROTEIN ACTIVITY AS WELL AS FURTHER EXPLORATION INTO THE ROLE OF TOOLKIT GENES IN GENE DUPLICATION AND DIVERGENCE. THE STUDY WAS PUBLISHED ONLINE NOVEMBER 12, 2020, IN GENES AND DEVELOPMENT. COMPREHENSIVE LISTS OF 2020 ORIGINAL RESEARCH PAPERS, REVIEWS, COMMENTARIES, CHAPTERS, AND BOOKS
ORIGINAL RESEARCH PAPERS	1. YEAST NUAK1 PHOSPHORYLATES HISTONE H3 THREONINE 11 IN LOW GLUCOSE STRESS BY THE COOPERATION OF AMPK AND CK2 SIGNALING. OH S, LEE J, SWANSON SK, FLORENS L, WASHBURN MP, WORKMAN JL. ELIFE. 2020;9:E64588 DOI: 64510.67554/ELIFE.64588. 2. THE PLASTICITY OF THE PYRUVATE DEHYDROGENASE COMPLEX CONFERS A LABILE STRUCTURE THAT IS ASSOCIATED WITH ITS CATALYTIC ACTIVITY. LEE J, OH S, BHATTACHARYA S, ZHANG Y, FLORENS L, WASHBURN MP, WORKMAN JL. PLOS ONE. 2020;15:E0243489. DOI: 10.1371/JOURNAL.PONE.0243489. 3. THE ROLE OF GENE DOSAGE IN BUDDING YEAST CENTROSOME SCALING AND SPONTANEOUS DIPLOIDIZATION. CHEN J, XIONG Z, MILLER DE, YU Z, MCCROSKEY S, BRADFORD WD, CAVANAUGH AM, JASPERSEN SL. PLOS GENET. 2020;16:E1008911. DOI: 1008910.1001371/JOURNAL.PGEN.1008911. 4. DRIVING INTEGRATIVE STRUCTURAL MODELING WITH SERIAL CAPTURE AFFINITY PURIFICATION. LIU X, ZHANG Y, WEN Z, HAO Y, BANKS CAS, LANGE JJ, SLAUGHTER BD, UNRUH JR, FLORENS L, ABMAYR SM, WORKMAN JL, WASHBURN MP. PROC NATL ACAD SCI U S A. 2020;117:31861-31870. 5. HIGH-THROUGHPUT IDENTIFICATION OF NUCLEAR ENVELOPE PROTEIN INTERACTIONS IN SCHIZOSACCHAROMYCES POMBE USING AN ARRAYED MEMBRANE YEAST-TWO HYBRID LIBRARY. VARBERG JM, GARDNER JM, MCCROSKEY S, SARAVANAN S, BRADFORD WD, JASPERSEN SL. G3 (BETHESDA). 2020. 6. SWR1-INDEPENDENT ASSOCIATION OF H2A.Z TO THE LINC COMPLEX PROMOTES MEIOTIC CHROMOSOME MOTION. GONZALEZ-ARRANZ S, GARDNER JM, YU Z, PATEL NJ, HELDRICH J, SANTOS B, CARBALLO JA, JASPERSEN SL, HOCHWAGEN A, SAN-SEGUNDO PA. FRONT CELL DEV BIOL. 2020;8:594092. 7. A SIX-AMINO-ACID MOTIF IS A MAJOR DETERMINANT IN FUNCTIONAL EVOLUTION OF HOX1 PROTEINS. SINGH NP, DE KUMAR B, PAULSON A, PARRISH ME, ZHANG Y, FLORENS L, CONAWAY JW, SI K, KRUMLAUF R. [PUBLISHED AHEAD OF PRINT NOVEMBER 14 2020]. GENES DEV. 2020. 8. IDENTIFICATION AND CHARACTERIZATION OF BREAKPOINTS AND MUTATIONS ON DROSOPHILA MELANOGASTER BALANCER CHROMOSOMES. MILLER DE, KAHSAI L, BUDDIKA K, DIXON MJ, KIM BY, CALVI BR, SOKOL NS, HAWLEY RS, COOK KR. G3(BETHESDA). 2020;10:4271-4285. 9. WTF4 MEIOTIC DRIVER UTILIZES CONTROLLED PROTEIN AGGREGATION TO GENERATE SELECTIVE CELL DEATH. NUCKOLLS NL, MOK AC, LANGE JJ, YI K, KANDOLA TS, HUNN AM, MCCROSKEY S, SNYDER JL, BRAVO NUNEZ MA, MCCLAIN M, MCKINNEY SA, WOOD C, HALFMANN R, ZANDERS SE. ELIFE. 2020;9:E55694. DOI: 55610.57554/ELIFE.55694. 10. THE MEDIATOR SUBUNIT, MED23 IS REQUIRED FOR EMBRYONIC SURVIVAL AND REGULATION OF CANONICAL WNT SIGNALING DURING CRANIAL GANGLIA DEVELOPMENT. DASH S, BHATT S, SANDELL L, SEIDEL C, AHN Y, KRUMLAUF R, TRAINOR P. FRONT PHYSIOL. 2020;11:531933. DOI: 531910.533389/FPHYS.532020.531933. 11. GENETIC BACKGROUND IMPACTS THE TIMING OF SYNAPTONEMAL COMPLEX BREAKDOWN IN DROSOPHILA MELANOGASTER. WESLEY ER, HAWLEY RS, BILLMYRE KK. [PUBLISHED AHEAD OF PRINT OCTOBER 18 2020]. CHROMOSOMA. 2020. 12. FLUID-MEDIATED FORCE ON A PARTICLE DUE TO AN OSCILLATING PLATE AND ITS EFFECT ON DEPOSITION MEASUREMENTS BY A QUARTZ CRYSTAL MICROBALANCE. FOUXON I, RUBINSTEIN B, WEINSTEIN O, LESHANSKY A. PHYS REV LETT. 2020;125:144501. 13. MATRIX METALLOPROTEASE-MEDIATED CLEAVAGE OF NEURAL GLIAL-RELATED CELL ADHESION MOLECULES ACTIVATES QUIESCENT OLFACTORY STEM CELLS VIA EGFR. CHEN ZH, LUO XC, YU CR, HUANG L. MOL CELL NEUROSCI. 2020;108:103552. 14. REGULATION OF SETD2 STABILITY IS IMPORTANT FOR THE FIDELITY OF H3K36ME3 DEPOSITION. BHATTACHARYA S, WORKMAN J. L. EPIGENTICS CHROMATIN. 2020;13:40. 15. EVALUATING THE EFFECTS OF CELL SORTING ON GENE EXPRESSION. BOX A, DELAY M, TIGHE S, CHITTUR SV, BERGERON A, COCHRAN M, LOPEZ P, MEYER EM, SALUK A, THORNTON S, BRUNDAGE K. J BIOMOL TECH : JBT. 2020;31:100-111. 16. HEDGEHOG SIGNALING IS REQUIRED FOR ENDOMESODERMAL PATTERNING AND GERM CELL DEVELOPMENT IN THE SEA ANEMONE NEMATOSTELLA VECTENSIS. CHEN CY, MCKINNEY SA, ELLINGTON LR, GIBSON MC. ELIFE. 2020;9:E54573. DOI:54510.54577.54554/ELIFE.54573. 17. ORIGINS AND EVOLUTIONARY PATTERNS OF THE 1.688 SATELLITE DNA FAMILY IN DROSOPHILA PHYLOGENY. DE LIMA LG, HANLON SL, GERTON JL. [PUBLISHED AHEAD OF PRINT SEPTEMBERG3 (BETHESDA). 2020;10. 18. DIFFERENTIAL COMPLEX FORMATION VIA PARALOGS IN THE HUMAN SIN3 PROTEIN INTERACTION NETWORK. ADAMS MK, BANKS CAS, THORNTON JL, KEMPF CG, ZHANG Y, MIAH S, HAO Y, SARDIU ME, KILLER M, HATTEM GL, MURRAY A, KATT ML, FLORENS L, WASHBURN MP. MOL CELL PROTEOMICS. 2020;19:1468-1484. 19. B-CATENIN AND ASSOCIATED PROTEINS REGULATE LINEAGE DIFFERENTIATION IN GROUND STATE MOUSE EMBRYONIC STEM CELLS. TAO F, SOFFERS J, HU D, CHED S, GAO X, ZHANG Y, ZHAO C, SMITH SE, UNRUH JR, ZHANG D, TSUCHIYA D, VENKATRAMAN A, ZHAO M, LI Z, QIAN P, PARMELY T, HE XC, WASHBURN M, FLORENS L, PERRY JM, ZEITLINGER J, WORKMAN J, LI L. STEM CELL REP. 2020;15:662-676. 20. FEEDING-DEPENDENT TENTACLE DEVELOPMENT IN THE SEA ANEMONE NEMATOSTELLA VECTENSIS. IKMI A, STEENBERGEN PJ, ANZO M, MCMULLEN MR, STOKKERMANS A, ELLINGTON LR, GIBSON MC. NAT COMMUN. 2020;11:4399. DOI: 4310.1038/S41467-41020-18133-41460. 21. CHANGES IN REGENERATION-RESPONSIVE ENHANCERS SHAPE REGENERATIVE CAPACITIES IN VERTEBRATES. WANG W, HU CK, ZENG A, ALEGRE D, HU D, GOTTING K, ORTEGA GRANILLO A, WANG Y, ROBB S, SCHNITTKER R, ZHANG S, ALEGRE D, LI H, ROSS E, ZHANG N, BRUNET A, SNCHEZ ALVARADO A. SCIENCE. 2020;369: EAAZ3090. DOI: 10.1126/SCIENCE.AAZ3090. 22. PAK1IP1 LOSS-OF-FUNCTION LEADS TO CELL CYCLE ARREST, LOSS OF NEURAL CREST CELLS, AND CRANIOFACIAL ABNORMALITIES. PANOUTSOPOULOS AA, DE CRESCENZO A, LEE A, LU AM, ROSS AP, YAROV-YAROVOY V, BORODINSKY L, MARCUCIO R, TRAINOR P, ZARBALIS K. FRONT CELL DEV BIOL. 2020;8:510063. DOI:510010.513389/FCELL.512020.510063. 23. ORDERLY ASSEMBLY UNDERPINNING BUILT-IN ASYMMETRY IN THE YEAST CENTROSOME DUPLICATION CYCLE REQUIRES CYCLIN-DEPENDENT KINASE. GEYMONAT M, PENG Q, GUO Z, YU Z, UNRUH JRJ, S. L., SEGAL M. ELIFE. 2020;9:E5922. DOI: 10.7554/ELIFE.59222. 24. ATYPICAL MEIOSIS CAN BE ADAPTIVE IN OUTCROSSED S. POMBE DUE TO WTF MEIOTIC DRIVERS. BRAVO NUNEZ MA, SABBARINI IM, EIDE LE, UNCKLESS RL, ZANDERS SE. ELIFE. 2020;9:E57936. DOI: 57910.57554/ELIFE.57936. 25. CRISPR-CAS13D INDUCES EFFICIENT MRNA KNOCKDOWN IN ANIMAL EMBRYOS. KUSHAWAH G, HERNANDEZ-HUERTAS L, ABUGATTAS-NUNEZ DEL PRADO J, MARTINEZ-MORALES JR, DEVORE ML, HASSAN H, MORENO-SANCHEZ I, TOMAS-GALLARDO L, DIAZ-MOSCOSO A, MONGES DE, GUELFO JR, THEUNE WC, BRANNAN EO, WANG W, CORBIN TJ, MORAN AM, SNCHEZ ALVARADO A, MALAGA-TRILLO E, TAKACS CM, BAZZINI AA, MORENO-MATEOS MA. DEV CELL. 2020;54:805817E807. 26. RETINOIC ACID SYNTHESIS AND AUTOREGULATION MEDIATE ZONAL PATTERNING OF VESTIBULAR ORGANS AND INNER EAR MORPHOGENESIS. ONO K, SANDELL LL, TRAINOR PA, WU DK. [PUBLISHED AHEAD OF PRINT AUGUST 7 2020]. DEVELOPMENT. 2020;147. 27. TRANSLATION OF SMALL DOWNSTREAM ORFS ENHANCES TRANSLATION OF CANONICAL MAIN OPEN READING FRAMES. WU Q, WRIGHT M, GOGOL MM, BRADFORD WD, ZHANG N, BAZZINI AA. EMBO J. 2020;39:E104763. DOI: 104710../EMBJ.2020104763. 28. ADAPTATION TO LOW PARASITE ABUNDANCE AFFECTS IMMUNE INVESTMENT AND IMMUNOPATHOLOGICAL RESPONSES OF CAVEFISH. PEU R, BOX AC, CHEN S, ET AL. [PUBLISHED ONLINE AHEAD OF PRINT, 2020 JUL 20]. NAT ECOL EVOL. 2020;10.1038/S41559-020-1234-2. DOI:10.1038/S41559-020-1234-2. 29. FAM20B-CATALYZED GLYCOSAMINOGLYCANS CONTROL MURINE TOOTH NUMBER BY RESTRICTING FGFR2B SIGNALING. WU J, TIAN Y, HAN L, LIU C, SUN T, LI L, YU Y, LAMICHHANE B, D'SOUZA RN, MILLAR SE, KRUMLAUF R, ORNITZ DM, FENG JQ, KLEIN O, ZHAO H, ZHANG F, LINHARDT RJ, WANG X. BMC BIOL. 2020;18:87. HTTPS://DOI.ORG/10.1186/S12915-12020-00813-12914. 30. WAMPA IS A DYNEIN SUBUNIT REQUIRED FOR AXONEMAL ASSEMBLY AND MALE FERTILITY IN DROSOPHILA. BAUERLY E, YI K, GIBSON MC. DEV BIOL. 2020;463:158-168.
31. TELOMERE-TO-TELOMERE ASSEMBLY OF A COMPLETE HUMAN X CHROMOSOME.	MIGA KH, KOREN S, RHIE A, ET AL. [PUBLISHED ONLINE AHEAD OF PRINT, 2020 JUL 14]. NATURE. 2020;10.1038/S41586-020-2547-7. DOI:10.1038/S41586-020-2547-7. 32. 37/67-LAMININ RECEPTOR FACILITATES NEURAL CREST CELL MIGRATION DURING ENTERIC NERVOUS SYSTEM DEVELOPMENT. FU M, BARLOW-ANACKER AJ, KURUVILLA KP, BOWLIN GL, SEIDEL CW, TRAINOR PA, FASEB J. 2020;34:10931-10947. 33. DYNAMIC RNA ACETYLATION REVEALED BY QUANTITATIVE CROSS-EVOLUTIONARY MAPPING. SAS-CHEN, A., THOMAS, J.M., MATZOV, D. ET. NATURE. 2020;583:638-643. HTTPS://DOI.ORG/10.1038/S41586-020-2418-2. 34. PERSISTENT DNA DAMAGE AND SENESCENSE IN THE PLACENTA IMPACTS DEVELOPMENTAL OUTCOMES OF EMBRYOS. VIJAY PRATAP SINGH, SEAN MCKINNEY, JENNIFER L. GERTON. [PUBLISHED AHEAD OF PRINT JUNE 16 2020]. DEV CELL. 2020. DOI: 10.1016/J.DEVCEL.2020.05.025. 35. OVERCOMING WNT-BETA-CATENIN DEPENDENT ANTICANCER THERAPY RESISTANCE IN LEUKAEMIA STEM CELLS. PERRY JM, TAO F, ROY A, LIN T, HE XC, CHEN S, LU X, NEMECHEK J, RUAN L, YU X, DUKES D, MORAN A, PACE J, SCHROEDER K, ZHAO M, VENKATRAMAN A, QIAN P, LI Z, HEMBREE M, PAULSON A, HE Z, XU D, TRAN TH, DESHMUKH P, NGUYEN CT, KASI RM, RYAN R, BROWARD M, DING S, GUEST E, AUGUST K, GAMIS AS, GODWIN A, SITTAMPALAM GS, WEIR SJ, LI L. NAT CELL BIOL. 2020;22:689-700. 36. VISUALIZING MESODERM AND NEURAL CREST CELL DYNAMICS DURING CHICK HEAD MORPHOGENESIS. MCKINNEY MC, MCLENNAN R, GINIUNAITE R, BAKER RE, MAINI PK, OTHMER HG, KULESA PM. DEV BIOL. 2020;461:184-196. 37. MERKEL CELL POLYOMAVIRUS ACTIVATES LSD1-MEDIATED BLOCKADE OF NON CANONICAL BAF TO REGULATE TRANSFORMATION AND TUMORIGENESIS. PARK DE, CHENG J, MCGRATH JP, LIM MY, CUSHMAN C, SWANSON SK, TILLGREN ML, PAULO JA, GOKHALE PC, FLORENS L, WASHBURN MP, TROJER P, DECAPRIO JA. NAT CELL BIOL. 2020;22:603-615. AUTHOR CORRECTION: NAT CELL BIOL. 2020;22:752. 38. DLP-MEDIATED HH AND WNT SIGNALING INTERDEPENDENCE IS CRITICAL IN THE NICHE FOR GERMLINE STEM CELL PROGENY DIFFERENTIATION. TU R, DUAN B, SONG X, XIE T. SCI ADV 2020;6:EAAZ0480. 39. THEORY OF HYDRODYNAMIC INTERACTION OF TWO SPHERES IN WALL-BOUNDED SHEAR FLOW. FOUXON I, RUBINSTEIN B, GE Z, BRANDT L, LESHANSKY A. PHYS REV FLUIDS. 2020;5:054101 DOI:054110.011103/PHYSREVFLUIDS.054105.054101. 40. INTEGRATIVE MODELING OF A SIN3/HDAC COMPLEX SUB-STRUCTURE. BANKS, C.A.S., ZHENG,Y., MIAH, S., HOA, Y., ADAMS, M. K., WEN, Z., THORNTON, J. L., FLORENS, L., WASHBURN, M. P. CELL REP. 2020:31;107516. DOI: 10.1016/J.CELREP. 41. FACTORS PROMOTING NUCLEAR ENVELOPE ASSEMBLY INDEPENDENT OF THE CANONICAL ESCRT PATHWAY. LEE IJ, STOKASIMOV E, DEMPSEY N, VARBERG JM, JACOB E, JASPERSEN SL, PELLMAN D. [PUBLISHED AHEAD OF PRINT APRIL 4 2020] J CELL BIOL. 2020:219;E201908232. 42. A SYSTEMS CHEMOPROTEOMIC ANALYSIS OF ACYL-COA/PROTEIN INTERACTION NETWORKS. LEVY MJ, MONTGOMERY DC, SARDIU ME, MONTANO JL, BERGHOLTZ SE, NANCE KD, THORPE AL, FOX SD, LIN Q, ANDRESSON T, FLORENS L, WASHBURN MP, MEIER JL. CELL CHEM BIOL. 2020;27:322-333.E5. 43. REGULATION OF THE RNAPII POOL IS INTEGRAL TO THE DNA DAMAGE RESPONSE. VIDAKOVIC AT, MITTER R, KELLY GP, NEUMANN M, HARREMAN M, MARTINEZ MR, HERLIHY A, WEEMS J, BOEING S, ENCHEVA V, GAUL L, MILLIGAN L, TOLLERVEY D, CONAWAY R, CONAWAY J, SNIJDERS AP, STEWART A, SVEJSTRUP JQ. CELL. 2020;180:1245-1261. 44. CRYO-EM STRUCTURE OF A NEURONAL FUNCTIONAL AMYLOID IMPLICATED IN MEMORY PERSISTENCE IN DROSOPHILA. HERVAS R, RAU MJ, PARK Y, ZHANG W, MURZIN AG, FITZPATRICK JAJ, SCHERES SHW, SI K. SCIENCE. 2020;367:1230-1234. 45. NRBP1-CONTAINING CUL2/CUL4A REGULATES AMYLOID BETA PRODUCTION BY TARGETING BRI2 AND BRI3 FOR DEGRADATION. YASUKAWA T, TSUTSUI A, TOMOMORI-SATO C, SOTO S, SARAF A, WASHBURN MP, FLORENS L, TERADA T, SHIMIZU K, CONAWAY RC, CONAWAY JW, ASO T. CELL REP. 2020;30:3478- 3491.E6. DOI: 10.1016/J.CELREP.2020.02.059. 46. INTER-RHOMBOMERIC INTERACTIONS REVEAL ROLES FOR FIBROBLAST GROWTH FACTORS SIGNALING IN SEGMENTAL REGULATION OF EPHA4 EXPRESSION. CAMBRONERO F, ARIZA-MCNAUGHTON L, WIEDEMANN LM, KRUMLAUF R. DEV DYN. 2020;249:354-368. 47. THE ROLE OF MEDIATOR AND LITTLE ELONGATION COMPLEX IN TRANSCRIPTION TERMINATION. TAKAHASHI H, RANJAN A, CHEN S, SUZUKI H, SHIBATA M, HIROSE T, HIROSE H, SASAKI K, ABE R, CHEN K, HE Y, ZHANG Y, TAKIGAWAI, TSUKIYAMA T, WATANABE M, FUJII S, IIDA M, YAMAMOTO J, YAMAGUCHI Y, SUZUKI Y, MATSUMOTO M, NAKAYAMA KI, WASHBURN MP, SARAF A, FLORENS L. SATO S, TOMOMORI-SATO C, CONAWAY RC, CONAWAY JW, HATAKEYAMA S. NAT COMMUN. 2020;11:1063. DOI: 10.1038/S41467-020-14849-1. 48. REGULATION OF POLO KINASE BY MATRIMONY IS REQUIRED FOR COHESIN MAINTENANCE DURING DROSOPHILA MELANOGASTER FEMALE MEIOSIS. BONNER AM, HUGHES SE, HAWLEY RS. CURR BIOL. 2020;30:715-722E713. 49. VERTEBRATE DIAPAUSE PRESERVES ORGANISMS LONG TERM THROUGH POLYCOMB COMPLEX MEMBERS. HU CK, WANG W, BRIND'AMOUR J, SINGH PP, REEVES GA, LORINCZ MC, SNCHEZ ALVARADO A, BRUNET A. SCIENCE. 2020;367:870-874. 50. SUPER-RESOLUTION MICROSCOPY-BASED BIMOLECULAR FLUORESCENCE COMPLEMENTATION TO STUDY PROTEIN COMPLEX ASSEMBLY AND CO-LOCALIZATION. CHEN J, YU Z, UNRUH JR, SLAUGHTER BD, JASPERSEN SL. BIO-PROTOCOL. 2020;10:E3524. DOI: 3510.21769/BIOPROTOC.23524. 51. DROSOPHILA YBX1 HOMOLOG YPS PROMOTES OVARIAN GERM LINE STEM CELL DEVELOPMENT BY PREFERENTIALLY RECOGNIZING 5-METHYLCYTOSINE RNAS. ZOU F, TU R, DUAN B, YANG Z, PING Z, SONG X, CHEN S, PRICE A, LI H, SCOTT A, PERERA A, LI S, XIE T. PROC NATL ACAD SCI U S A. 2020;117:3603-3609. 52. DRAMATICALLY DIVERSE SCHIZOSACCHAROMYCES POMBE WTF MEIOTIC DRIVERS ALL DISPLAY HIGH GAMETE-KILLING EFFICIENCY. BRAVO NUNEZ MA, SABBARINI IM, EICKBUSH MT, LIANG Y, LANGE JJ, KENT AM, ZANDERS SE. PLOS GENET. 2020;16:E1008350. DOI: 1008310.1001371/JOURNAL.PGEN.1008350. 53. COMPARATIVE TRANSCRIPTOME ANALYSIS OF WILD AND LAB POPULATIONS OF ASTYANAX MEXICANUS UNCOVERS DIFFERENTIAL EFFECTS OF ENVIRONMENT AND MORPHOTYPE ON GENE EXPRESSION. KRISHNAN J, PERSONS JL, PEUSS R, HASSAN H, KENZIOR A, XIONG S, OLSEN L, MALDONADO E, KOWALKO JE, ROHNER N. [PUBLISHED AHEAD OF PRINT FEBRUARY 6 2020]. J EXP ZOOL B MOL DEV EVOL. 2020. 54. SYNAPTONEMAL COMPLEX-DEFICIENT DROSOPHILA MELANOGASTER FEMALES EXHIBIT RARE DSB REPAIR EVENTS, RECURRENT COPY-NUMBER VARIATION, AND AN INCREASED RATE OF DE NOVO TRANSPOSABLE ELEMENT MOVEMENT. MILLER DE. G3 (BETHESDA). 2020;10:525-537. 55. THE CHROMATIN BOUND PROTEOME OF THE HUMAN MALARIA PARASITE. BATUGEDARA G, LU XM, SARAF A, SARDIU ME, CORT A, ABEL S, PRUDHOMME J, WASHBURN MP, FLORENS L, BUNNIK EM, LE ROCH KG. MICROB GENOM. 2020;6:E000327. DOI: 000310.001099/MGEN.000320.000327. 56. STRIPAK DIRECTS PP2A ACTIVITY TOWARD MAP4K4 TO PROMOTE ONCOGENIC TRANSFORMATION. KIM JW, BERRIOS C, KIM M, SCHADE AE, ADELMANT G, YEERNA H, DAMATO E, INIGUEZ AB, FLORENS L, WASHBURN MP, STEGMAIER K, GRAY NS, TAMAYO P, GJOERUP O, MARTO JA, DECAPRIO J, HAHN WC. ELIFE. 2020;9. DOI: 10.7554/ELIFE.53003. 57. NEURAL CREST CELLS BULLDOZE THROUGH THE MICROENVIRONMENT USING AQUAPORIN-1 TO STABILIZE FILOPODIA. MCLENNAN R, MCKINNEY MC, TEDDY JM, MORRISON JA, KASEMEIER-KULESA JC, RIDENOUR DA, MANTHE CA, GINIUNAITER, ROBINSON M, BAKER RE, MAINI PK, KULESA PM. DEVELOPMENT. 2020;147:DEV185231. DOI:10.1242/DEV.185231. 58. THE MONARCH INITIATIVE IN 2019: AN INTEGRATIVE DATA AND ANALYTIC PLATFORM CONNECTING PHENOTYPES TO GENOTYPES ACROSS SPECIES. SHEFCHEKKA, HARRIS NL, GARGANO M, MATENTZOGLU N, UNNI D, BRUSH M, KEITH D, CONLIN T, VASILEVSKY N, ZHANG XA, BALHOFF JP, BABB L, BELLO SM, BLAU H, BRADFORD Y, CARBON S, CARMODY L, CHAN LE, CIPRIANI V, CUZICK A, ROCCA MD, DUNN N, ESSAID S, FEY P, GROVE C, GOURDINE JP, HAMOSH A, HARRIS M, HELBIG I, HOATLIN M, JOACHIMIAK M, JUPP S, LETT KB, LEWIS SE, MCNAMARA C, PENDLINGTON ZM, PILGRIM C, PUTMAN T, RAVANMEHR V, REESE J, RIGGS E, ROBB S, RONCAGLIA P, SEAGER J, SEGERDELL E, SIMILUK M, STORM AL, THAXON C, THESSEN A, JACOBSEN JOB, MCMURRY JA, GROZA T, KOHLER S, SMEDLEY D, ROBINSON PN, MUNGALL CJ, HAENDEL MA, MUNOZ-TORRES MC, OSUMI-SUTHERLAND D. NUCLEIC ACIDS RES. 2020;48:D704-D715. 59. MED23 REGULATES SOX9 EXPRESSION DURING CRANIOFACIAL DEVELOPMENT. DASH S, BHATT S, FALCON KT, SANDELL LL, TRAINOR PA. J DENT RES. 2021;100:406-414. FIRST PUBLISHED NOVEMBER 6, 2020.
REVIEWS, COMMENTARIES, CHAPTERS, AND BOOKS	1. INTRODUCTION TO THE SPECIAL ISSUE - CAVEFISH - ADAPTATION TO THE DARK. KOWALKO JE, FRANZ-ODENDAAL TA, ROHNER N. J EXP ZOO PT B MOL DEV EVOL. 2020;334:393-396./ 2. SEVEN MYTHS OF HOW TRANSCRIPTION FACTORS READ THE CIS-REGULATORY CODE. ZEITLINGER J. CURR OPIN SYST BIOL. 2020;23:22-31. 3. RESISTANCE TO NATURAL AND SYNTHETIC GENE DRIVE SYSTEMS. PRICE TAR, WINDBICHLER N, UNCKLESS RL, SUTTER A, RUNGE JN, ROSS PA, POMIANKOWSKI A, NUCKOLLS NL, MONTCHAMP-MOREAU C, MIDEO N, MARTIN OY, MANSER A, LEGROS M, LARRACUENTE AM, HOLMAN L, GODWIN J, GEMMELL N, COURRET C, BUCHMAN A, BARRETT LG, LINDHOLM AK. J EVOL BIOL. 2020;33:1345-1360. 4. ANATOMY OF THE FUNGAL MICROTUBULE ORGANIZING CENTER, THE SPINDLE POLE BODY. JASPERSEN SL. ANATOMY OF THE FUNGAL MICROTUBULE ORGANIZING CENTER, THE SPINDLE POLE BODY. CURR OPIN STRUCT BIOL. 2020;66:22-31. 5. THE SAGA CHROMATIN-MODIFYING COMPLEX: THE SUM OF ITS PARTS IS GREATER THAN THEWHOLE. SOFFERS JHM, WORKMAN JL. GENES DEV. 2020;34:1287-1303. 6. IMPLICATIONS OF THE ORB2 AMYLOID STRUCTURE IN HUNTINGTON'S DISEASE. HERVAS R, MURZIN AG, SI K. INT J MOL SCI. 2020;21:E6910. DOI: 6910.3390/IJMS21186910. 7. TO BEAD OR NOT TO BEAD? THAT IS THE QUESTION WITH CROSS-LINKING MASS SPECTROMETRY. FLORENS L, HAO Y, ZHANG Y, WEN Z, BANKS CAS, WASHBURN MP. J BIOMOL TECH : JBT. 2020;31:S24. 8. ALTERNATIVE SYNAPTONEMAL COMPLEX STRUCTURES: TOO MUCH OF A GOOD THING?. HUGHES SE, HAWLEY RS. [PUBLISHED AHEAD OF PRINT AUGUST 13 2020]. TRENDS GENET. 2020. 9. IN THE SPOTLIGHT-EARLY CAREER RESEARCHER. ROHNER N. J EXP ZOOL PT B MOL DEV EVOL. 2020;334:387-388. 10. THE SOCIETY FOR CRANIOFACIAL GENETICS AND DEVELOPMENTAL BIOLOGY 42ND ANNUAL MEETING. EISENHOFFER GT, JR., CLOUTHIER D, COX T, SAINT-JEANNET JP, TANEYHILL LA, TRAINOR PA, MOODY SA. AM J MED GENET A. 2020;182:1555-1561. 11. A HOX GENE REGULATORY NETWORK FOR HINDBRAIN SEGMENTATION. PARKER HJ, KRUMLAUF R. CURR TOP DEV BIOL. 2020;139:169-203. 12. OVERCOMING RESISTANCE TO IMMUNOTHERAPY BY TEACHING OLD DRUGS NEW TRICKS. PERRY JM, LI L. MOL CELL ONCOL. 2020;7:E1801088. DOI:10.1080/23723556.2020.1801088. 13. A REVIEW ON HISTOTECHNOLOGY PRACTICES IN COVID-19 PATHOLOGY INVESTIGATIONS. MALLOY S, WANG Y.[PUBLISHED ONLINE AHEAD OF PRINT JULY 2020]. J HISTOTECHNOL. 2020;1-6. DOI:10.1080/01478885.2020.1779484. 14. NEW AND IMPROVED TOOLS FOR THE OMICS CREW. FLORENS, L., DONG, M.-Q., LABAER, J. J PROTEOME RES 2020;19:2525-2528. DOI:10.1021/ACS.JPROTEOME.0C00328. 15. SAGA STRUCTURES PROVIDE MECHANISTIC MODELS FOR GENE ACTIVATION. SOFFERS JHM, POPOVA VV, WORKMAN JLW. TRENDS BIOCHEM SCI. 2020;45:547-549. 16. MEIOTIC DRIVE. SRINIVASA AN, ZANDERS SE. MEIOTIC DRIVE. CURR BIOL. 2020;30:R627-R629. 17. THE DEVELOPMENT, PATTERNING AND EVOLUTION OF NEURAL CREST CELL DIFFERENTIATION INTO CARTILAGE AND BONE. DASH S, TRAINOR P. [PUBLISHED ONLINE AHEAD OF PRINT MAY 14 2020]. BONE. 2020;115409. DOI:10.1016/J.BONE.2020.115409. 18. IDENTIFYING VITAMIN A SIGNALING BY VISUALIZING GENE AND PROTEIN ACTIVITY, AND BY QUANTIFICATION OF VITAMIN A METABOLITES. SHANNON SR, YU J, DEFNET AE, BONGFELDT D, MOISE AR, KANE MA, TRAINOR PA. METHODS ENZYMOL. 2020;637:367-418. 19. GENERATION AND ISOLATION OF RECOMBINANT RETINOID OXIDOREDUCTASE COMPLEX. ADAMS MK, BELYAEVA OV, KEDISHVILI NY. METHODS ENZYMOL. 2020;637:77-93. 20. A REVIEW OF THE SCIENTIFIC RIGOR, REPRODUCIBILITY, AND TRANSPARENCY STUDIES CONDUCTED BY THE ABRF RESEARCH GROUPS. MISCHE SM, FISHER NC, MEYN SM, SOL-CHURCH K, HEGSTAD-DAVIES RL, WEIS-GARCIA F, ADAMS M, ASHTON JM, DELVENTHAL KM, DRAGON JA, HOLMES L, JAGTAP P, KUBOW KE, MASON CE, PALMBLAD M, SEARLE BC, TURCK CW, KNUDTSON KL. JBT. 2020;31:11-26. 21. MEIOSIS: LOCATION, LOCATION, LOCATION, HOW CROSSOVERS ENSURE SEGREGATION. HUGHES, S. E., HAWLEY, R. S. CURR BIOL. 2020 APR 6;30(7):R311-R313 22. AN INTERDISCIPLINARY APPROACH TO INVESTIGATE COLLECTIVE CELL MIGRATION IN NEURAL CREST. GINIUNAITE R, MCLENNAN R, MCKINNEY MC, BAKER RE, KULESA PM, MAINI PK. DEV DYN. 2020;249:270-280. 23. ATLAS OF THE HUMAN INTESTINE. HE XC, LI L. ATLAS OF THE HUMAN INTESTINE. J EXP MED. 2020;217:E20191997. DOI:20191910.20191084/JEM.20191997. 24. WHEN HISTONES ARE UNDER GLUCOSE STARVATION. LEE J, OH S, ABMAYR SM, WORKMAN JL. J BIOSCI. 2020;45:E17. 25. INTESTINAL EPITHELIAL REGENERATION: ACTIVE VERSUS RESERVE STEM CELLS AND PLASTICITY MECHANISMS. KARMAKAR S, DENG L, HE XC, LI L. AM J PHYSIOL GASTROINTEST LIVER PHYSIOL. 2020;318:G796-G802. 26. MODELLING COLLECTIVE CELL MIGRATION: NEURAL CREST AS A MODEL PARADIGM. GINIUNAITE R, BAKER RE, KULESA PM, MAINI PK. J MATH BIOL. 2020;80:481-04. 27. EXPORT AND TRANSPORTATION OF ZEBRAFISH. BARTON CL, BAUMANN DP, COX JD. IN: SC CARTNER, JS EISEN, SC FARMER, KJ GUILLEMIN, ML KENT, AND GE SANDERS, EDS. THE ZEBRAFISH IN BIOMEDICAL RESEARCH : BIOLOGY, HUSBANDRY, DISEASE, AND RESEARCH APPLICATIONS. ACADEMIC PRESS; 2020:443-450. 28. UNCEASINGLY SEARCHING FOR ANSWERS - AN INTERVIEW WITH CLAUDIO STERN. SNCHEZ-ALVARADO A. INT J DEV BIOL. 2021;65:131-136. EPUB 2020. 29. DARK WORLD RISES: THE EMERGENCE OF CAVEFISH AS A MODEL FOR THE STUDY OF EVOLUTION, DEVELOPMENT, BEHAVIOR, AND DISEASE. MCGAUGH SE, KOWALKO JE, DUBOUE E, LEWIS P, FRANZ-ODENDAAL TA, ROHNER N, GROSS JB, KEENE AC. J EXP ZOOL B MOL DEV EVOL. 2020 NOV;334(7-8):397-404. DOI: 10.1002/JEZ.B.22978. EPUB 2020 JUL 7. COMPETITIVE RESEARCH GRANT FUNDING & RESEARCH AWARDS & DISTINCTIONS THE ABILITY OF SIMR SCIENTISTS TO RECEIVE COMPETITIVELY AWARDED RESEARCH FUNDING ATTESTS TO THE HIGH LEVEL OF RESEARCH PRODUCTIVITY PRESENT AT SIMR. DURING 2020, SIMR SCIENTISTS WORKED WITH THE SUPPORT OF THIRTY-NINE GRANTS AND FELLOWSHIPS FROM THE NATIONAL INSTITUTES OF HEALTH, THREE GRANTS FROM THE NATIONAL SCIENCE FOUNDATION, ONE GRANT FROM THE MARCH OF DIMES, ONE GRANT FROM THE GREATER KANSAS CITY COMMUNITY FOUNDATION, ONE FELLOWSHIP FROM THE JANE COFFIN CHILDS MEMORIAL FUND, ONE AWARD FROM THE SEARLE SCHOLARS PROGRAM, ONE AWARD FROM THE PEW CHARITABLE TRUSTS, ONE AWARD FROM THE UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION, ONE GRANT FROM THE EDWARD MALLINCKRODT JR. FOUNDATION, ONE GRANT FROM THE JUVENILE DIABETES RESEARCH FOUNDATION, ONE GRANT FROM THE AMERICAN CANCER SOCIETY, ONE GRANT FROM THE SOCIETY FOR DEVELOPMENTAL BIOLOGY, ONE FROM THE ST. BALDRICK'S FOUNDATION AND ONE INVESTIGATOR AWARD FROM THE HOWARD HUGHES MEDICAL INSTITUTE. SUPPORT FROM NEW AND CONTINUING AWARDS TO SIMR TOTALED MORE THAN $6.7 MILLION IN 2020 TO SUPPLEMENT INCOME FROM ITS ENDOWMENTS. TESTIFYING TO THE HIGH LEVEL OF ACHIEVEMENT TAKING PLACE AT SIMR ARE THE AWARDS AND HONORS SIMR MEMBERS RECEIVED IN 2020: 1. JOAN CONAWAY, PHD, WAS ELECTED TO THE NATIONAL ACADEMY OF SCIENCES. 2. NICOLAS ROHNER, PHD, WAS AWARDED A FIVE-YEAR NIH DIRECTOR'S NEW INNOVATOR AWARD. HE ALSO RECEIVED A ONE-TIME SUBCONTRACT GRANT FROM BIONEXUS KC. 3. SARAH ZANDERS, PHD, WAS NAMED ONE OF SCIENCE NEWS' 2020 SN 10: SCIENTISTS TO WATCH. 4. KAUSIK SI RECEIVED A FIVE-YEAR NIH GRANT FROM THE NATIONAL INSTITUTE ON AGING AND AN NIH GRANT RENEWAL PROVIDING FIVE MORE YEARS OF FUNDING FROM THE NATIONAL INSTITUTE OF MENTAL HEALTH. 5. RON YU, PHD, WAS AWARDED A ONE-YEAR SUPPLEMENT FOR HIS NIH GRANT FROM THE NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS. 6. ARIEL BAZZINI, PHD, RECEIVED A FIVE-YEAR GRANT FROM THE NIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES. 7. RANDAL HALFMANN, PHD, WAS AWARDED A THREE-YEAR RESEARCH SCHOLAR GRANT FROM THE AMERICAN CANCER SOCIETY. 8. PAUL KULESA, PHD, RECEIVED A ONE-YEAR GRANT FROM THE ST. BALDRICK'S FOUNDATION. 9. YONGFU WANG, PHD, HEAD OF HISTOLOGY, WAS AWARDED THE LEICA LEADERSHIP IN MANAGEMENT AWARD FROM THE NATIONAL SOCIETY FOR HISTOTECHNOLOGY. 10. KATIE BILLMYRE, PHD, A POSTDOCTORAL RESEARCHER IN THE HAWLEY LAB, WAS AWARDED A FIVE-YEAR NIH PATHWAY TO INDEPENDENCE FELLOWSHIP AND A ONE-TIME DELILL NASSER AWARD FOR PROFESSIONAL DEVELOPMENT FROM THE GENETICS SOCIETY OF AMERICA. 11. SOMA DASH, PHD, A POSTDOCTORAL RESEARCHER IN THE TRAINOR LAB, WAS RECOGNIZED WITH A ONE-TIME FELLOWSHIP FROM THE AMERICAN ASSOCIATION FOR ANATOMY. 12. JEREMY SANDLER, PHD, A POSTDOCTORAL RESEARCHER IN THE PIOTROWSKI LAB, WAS AWARDED A ONE-YEAR GRANT FROM THE NIH NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS. 13. NATASHA SHYLO HYSON, PHD, A POSTDOCTORAL RESEARCHER IN THE TRAINOR LAB, WAS AWARDED A ONE-TIME EMERGING RESEARCH ORGANISMS GRANT FROM THE SOCIETY OF DEVELOPMENTAL BIOLOGY.
14. QIUSHUANG WU, A PREDOCTORAL RESEARCHER OF THE GRADUATE SCHOOL OF THE	STOWERS INSTITUTE IN THE BAZZINI LAB, RECEIVED A SIX-YEAR NIH PREDOCTORAL TO POSTDOCTORAL FELLOW TRANSITION AWARD. 15. ALEJANDRO RODRIGUEZ GAMA, A PREDOCTORAL RESEARCHER OF THE GRADUATE SCHOOL OF THE STOWERS INSTITUTE IN THE HALFMANN LAB, RECEIVED A SIX-YEAR NIH PREDOCTORAL TO POSTDOCTORAL FELLOW TRANSITION AWARD. 16. ALEXANDRIA COCKRELL, A PREDOCTORAL RESEARCHER FROM THE UNIVERSITY OF KANSAS MEDICAL CENTER IN THE GERTON LAB, RECEIVED A ONE-YEAR NIH GRANT FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES. INDEPENDENT RESEARCH PROGRAM LEADERS LABORATORIES INDIVIDUAL SCIENTISTS AT THE SIMR SPECIALIZE IN THE STUDY OF ONE OR MORE PARTICULAR GENES, PROTEINS, OR OTHER MOLECULES, EACH OF WHICH MAY CAUSE OR INFLUENCE VARIOUS KINDS OF DISEASE. A COMPREHENSIVE LIST OF RESEARCH LEADERS FOLLOWS: 1. ALEJANDRO SNCHEZ ALVARADO, PHD, EXECUTIVE DIRECTOR AND CHIEF SCIENTIFIC OFFICER, INVESTIGATOR, AND HOWARD HUGHES MEDICAL INSTITUTE INVESTIGATOR, JOINED SIMR IN 2011 FROM THE UNIVERSITY OF UTAH'S SCHOOL OF MEDICINE, WHERE HE HELD THE H.A. & EDNA BENNING PROFESSORSHIP OF EUROBIOLOGY AND ANATOMY. HE RECEIVED A BS IN MOLECULAR BIOLOGY AND CHEMISTRY FROM VANDERBILT UNIVERSITY IN NASHVILLE, TENNESSEE, AND A PHD IN PHARMACOLOGY AND CELL BIOPHYSICS FROM THE UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE IN CINCINNATI, OHIO. RESEARCH FOCUS: THE MOLECULAR AND CELLULAR MECHANISMS UNDERPINNING ANIMAL REGENERATION USING THE PLANARIAN SCHMIDTEA MEDITERRANEA AND OTHER RESEARCH ORGANISMS. 2. ARIEL BAZZINI, PHD, ASSISTANT INVESTIGATOR, JOINED SIMR IN 2016 FROM THE LAB OF ANTONIO J. GIRALDEZ, PHD, IN THE DEPARTMENT OF GENETICS AT YALE UNIVERSITY, WHERE HE COMPLETED A POSTDOCTORAL FELLOWSHIP. BAZZINI RECEIVED HIS PHD IN MOLECULAR BIOLOGY AT THE UNIVERSITY OF BUENOS AIRES, ARGENTINA. FOR HIS DOCTORAL DISSERTATION, HE STUDIED PLANT GENETICS AT THE INSTITUTE OF BIOTECHNOLOGY IN ARGENTINA'S NATIONAL INSTITUTE OF AGRICULTURAL TECHNOLOGY (INTA). RESEARCH FOCUS: THE REGULATION OF GENE EXPRESSION IN VERTEBRATES. 3. JOAN CONAWAY, PHD, INVESTIGATOR, JOINED SIMR IN 2001 FROM THE OKLAHOMA MEDICAL RESEARCH FOUNDATION WHERE SHE WAS AN ASSOCIATE INVESTIGATOR OF THE HOWARD HUGHES MEDICAL INSTITUTE AND INTERIM HEAD OF THE PROGRAM IN MOLECULAR AND CELL BIOLOGY. CONAWAY RECEIVED HER DOCTORATE IN CELL BIOLOGY FROM STANFORD UNIVERSITY SCHOOL OF MEDICINE. RESEARCH FOCUS: ANALYSIS OF THE MOLECULAR MECHANISM AND REGULATION OF GENE TRANSCRIPTION. 4. RONALD CONAWAY, PHD, INVESTIGATOR, JOINED SIMR IN 2001 FROM THE OKLAHOMA MEDICAL RESEARCH FOUNDATION WHERE HE WAS HOLDER OF THE CHAPMAN CHAIR IN MEDICAL RESEARCH. CONAWAY RECEIVED HIS PHD IN BIOCHEMISTRY FROM STANFORD UNIVERSITY SCHOOL OF MEDICINE. RESEARCH FOCUS: ANALYSIS OF THE MOLECULAR MECHANISM AND REGULATION OF GENE TRANSCRIPTION. 5. JENNIFER GERTON, PHD, INVESTIGATOR, JOINED SIMR IN 2002 FROM A POSTDOCTORAL FELLOWSHIP IN THE LABORATORY OF JOSEPH DERISI, PHD, IN THE DEPARTMENT OF BIOCHEMISTRY AND BIOPHYSICS AT THE UNIVERSITY OF CALIFORNIA-SAN FRANCISCO. GERTON RECEIVED A PHD IN MICROBIOLOGY AND IMMUNOLOGY FROM STANFORD UNIVERSITY. RESEARCH FOCUS: GENOMIC AND GENETIC ANALYSIS OF CHROMOSOME SEGREGATION AND CHROMOSOME DYNAMICS. 6. MATTHEW GIBSON, PHD, INVESTIGATOR AND DEAN OF THE GRADUATE SCHOOL, JOINED SIMR IN 2006 FROM A JANE COFFIN CHILDS MEMORIAL FUND POSTDOCTORAL FELLOWSHIP WITH NORBERT PERRIMON, PHD, AT HARVARD MEDICAL SCHOOL. GIBSON RECEIVED A PHD IN ZOOLOGY FROM THE UNIVERSITY OF WASHINGTON. RESEARCH FOCUS: GENETIC ANALYSIS OF MECHANISMS CONTROLLINGSIGNAL TRANSDUCTION, CELL PROLIFERATION, AND EPITHELIAL MORPHOGENESIS DURING DROSOPHILA DEVELOPMENT. 7. RANDAL HALFMANN, PHD, ASSOCIATE INVESTIGATOR, JOINED SIMR IN 2015 FROM THE UNIVERSITY OF TEXAS (UT) SOUTHWESTERN MEDICAL CENTER. HE RECEIVED A PHD IN BIOLOGY FROM THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY, WHERE HE WAS A NATIONAL SCIENCE FOUNDATION PREDOCTORAL FELLOW. AFTER COMPLETING HIS GRADUATE STUDIES, HALFMANN OBTAINED AN INDEPENDENT POSITION AT UT SOUTHWESTERN MEDICAL CENTER WHERE HE WAS A SARA AND FRANK MCKNIGHT FELLOW AND RECEIVED A DIRECTOR'S EARLY INDEPENDENCE AWARD FROM THE NATIONAL INSTITUTES OF HEALTH. RESEARCH FOCUS: CELLULAR AND EVOLUTIONARY IMPLICATIONS OF PROTEIN SELF-ASSEMBLY USING GENETIC, BIOCHEMICAL, AND CELL-BIOLOGICAL APPROACHES. 8. R. SCOTT HAWLEY, PHD, INVESTIGATOR AND DEAN EMERITUS OF THE GRADUATE SCHOOL, JOINED SIMR IN 2001 FROM THE UNIVERSITY OF CALIFORNIA-DAVIS WHERE HE WAS A PROFESSOR OF GENETICS IN THE MOLECULAR AND CELLULAR BIOLOGY SECTION. HAWLEY EARNED A PHD IN GENETICS FROM THE UNIVERSIT OF WASHINGTON AND COMPLETED POSTDOCTORAL TRAINING AS A HELEN HAY WHITNEY FELLOW AT THE INSTITUTE FOR CANCER RESEARCH IN PHILADELPHIA. RESEARCH FOCUS: INVESTIGATION OF MECHANISMS THAT INFLUENCE HOW CHROMOSOMES PAIR AND SEGREGATE DURING MEIOSIS USING DROSOPHILA AS AN EXPERIMENTAL SYSTEM. 9. SUE JASPERSEN, PHD, ASSOCIATE INVESTIGATOR, JOINED SIMR IN 2005 FRO THE LABORATORY OF MARK WINEY, PHD, AT THE UNIVERSITY OF COLORADO-BOULDER WHERE SHE WAS A KECK FOUNDATION FELLOW, A HELEN HAY WHITNEY FELLOW, AND THE RECIPIENT OF A LEUKEMIA & LYMPHOMA SOCIETY CAREER DEVELOPMENT AWARD. JASPERSEN HOLDS A PHD IN BIOCHEMISTRY FROM THE UNIVERSITY OF CALIFORNIA-SAN FRANCISCO. RESEARCH FOCUS: INNER NUCLEAR MEMBRANE PROTEIN LOCALIZATION AND ROLE IN CHROMOSOME POSITIONING AND SEGREGATION. 10. ROBERT KRUMLAUF, PHD, SCIENTIFIC DIRECTOR EMERITUS AND INVESTIGATOR, JOINED THE SIMR IN 2000 FROM ENGLAND'S NATIONAL INSTITUTE FOR MEDICAL RESEARCH, THE RIDGEWAY, MILL HILL, LONDON, WHERE HE WAS HEAD OF THE DIVISION OF DEVELOPMENTAL NEUROBIOLOGY. KRUMLAUF RECEIVED A PHD IN DEVELOPMENTAL BIOLOGY FROM OHIO STATE UNIVERSITY. RESEARCH FOCUS: ANALYSIS OF MOLECULAR PATHWAYS THAT REGULATE HOW THE MAMMALIAN HEAD, BRAIN AND NERVOUS SYSTEM ARE BUILT, USING A VARIETY OF VERTEBRATE RESEARCH ORGANISMS. 11. LINHENG LI, PHD, INVESTIGATOR, JOINED SIMR IN 2000 FROM THE UNIVERSITY OF WASHINGTON MEDICAL CENTER WHERE HE HELD A FACULTY APPOINTMENT AFTER COMPLETING POSTDOCTORAL TRAINING IN THE LABORATORY DIRECTED BY LEROY HOOD, MD, PHD. LI EARNED HIS PHD IN MOLECULAR AND CELLULAR BIOLOGY FROM NEW YORK UNIVERSITY MEDICAL SCHOOL UNDER THE MENTORING OF EDWARD ZIFF, PHD. RESEARCH FOCUS: INVESTIGATION OF MOLECULAR AND GENETIC PATHWAYS CONTROLLING ADULT STEM CELL DEVELOPMENT IN THE HEMATOPOIETIC AND INTESTINAL SYSTEMS USING TRANSGENIC AND GENE TARGETING ANIMAL MODEL APPROACHES. 12. TATJANA PIOTROWSKI, PHD, INVESTIGATOR, JOINED SIMR IN 2011 FROM THE UNIVERSITY OF UTAH'S SCHOOL OF MEDICINE, WHERE SHE WAS AN ASSOCIATE PROFESSOR IN THE DEPARTMENT OF NEUROBIOLOGY AND ANATOMY. SHE RECEIVED HER MASTER'S DEGREE FROM THE UNIVERSITY OF TUBINGEN, GERMANY, AND HER DOCTORATE DEGREE FROM THE MAX PLANCK INSTITUTE FOR DEVELOPMENTAL BIOLOGY IN TUBINGEN. RESEARCH FOCUS: COLLECTIVE CELL MIGRATION, CELL TYPE SPECIFICATION, AND STEM CELL BIOLOGY IN ZEBRAFISH AS A RESEARCH SYSTEM. 13. NICOLAS ROHNER, PHD, ASSOCIATE INVESTIGATOR, JOINED SIMR IN 2015 FROM HARVARD MEDICAL SCHOOL, WHERE HE WAS A POSTDOCTORAL FELLOW IN THE LABORATORY OF CLIFF TABIN, PHD. ROHNER EARNED A PHD IN BIOLOGY FROM THE MAX PLANCK INSTITUTE FOR DEVELOPMENTAL BIOLOGY IN TUBINGEN, GERMANY. RESEARCH FOCUS: GENETIC MECHANISMS AND MUTATIONS THAT UNDERLIE THE ANIMAL KINGDOM'S TREMENDOUS DIVERSITY IN MORPHOLOGY, PHYSIOLOGY, AND BEHAVIOR. 14. KAUSIK SI, PHD, ASSOCIATE SCIENTIFIC DIRECTOR AND INVESTIGATOR, JOINED SIMR IN 2005 FROM THE LABORATORY OF ERIC KANDEL, MD, AT COLUMBIA UNIVERSITY CENTER FOR NEUROBIOLOGY AND BEHAVIOR WHERE HE WAS A JANE COFFIN CHILDS FELLOW AND A FRANCIS GOELET FELLOW IN NEUROSCIENCE. SI EARNED A PHD IN MOLECULAR BIOLOGY FROM THE ALBERT EINSTEIN COLLEGE OF MEDICINE. RESEARCH FOCUS: ROLE OF SYNAPTIC PROTEIN SYNTHESIS IN INFORMATION ACQUISITION AND MEMORY STORAGE. 15. PAUL TRAINOR, PHD, INVESTIGATOR, JOINED SIMR IN 2001 FROM A RESEARCH POSITION AT THE NATIONAL INSTITUTE FOR MEDICAL RESEARCH AT MILL HILL, LONDON, WHERE HE COMPLETED POSTDOCTORAL TRAINING. TRAINOR HAS A PHD IN DEVELOPMENTAL BIOLOGY FROM CHILDREN'S MEDICAL RESEARCH INSTITUTE AT THE UNIVERSITY OF SYDNEY, AUSTRALIA. RESEARCH FOCUS: INVESTIGATION OF THE INTERACTIONS BETWEEN DISTINCT TISSUES IN THE BODY AND THEIR REGULATION DURING NORMAL DEVELOPMENT TO REVEAL PATHWAYS THAT REGULATE NORMAL CRANIAL AND FACIAL DEVELOPMENT. 16. JERRY WORKMAN, PHD, INVESTIGATOR, JOINED SIMR IN 2003 FROM THE PENNSYLVANIA STATE UNIVERSITY WHERE HE HELD THE PAUL BERG PROFESSORSHIP OF BIOCHEMISTRY AND WAS AN ASSOCIATE INVESTIGATOR OF THE HOWARD HUGHES MEDICAL INSTITUTE. WORKMAN EARNED A PHD IN CELL AND MOLECULAR BIOLOGY FROM THE UNIVERSITY OF MICHIGAN AND COMPLETED POSTDOCTORAL TRAINING AT THE ROCKEFELLER UNIVERSITY WITH BOB ROEDER,PHD. RESEARCH FOCUS: STUDY OF THE PROTEIN COMPLEXES THAT MODIFY CHROMATIN.
17. TING XIE, PHD, INVESTIGATOR, JOINED SIMR IN 2000 AFTER COMPLETING A	HOWARD HUGHES MEDICAL INSTITUTE POSTDOCTORAL FELLOWSHIP IN THE LABORATORY OF ALLAN C. SPRADLING, PHD, AT THE CARNEGIE INSTITUTION OF WASHINGTON. XIE RECEIVED HIS PHD FROM THE JOINT GRADUATE PROGRAM IN MOLECULAR BIOLOGY AND BIOCHEMISTRY OF RUTGERS UNIVERSITY AND THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY. RESEARCH FOCUS: GENETIC AND MOLECULAR ANALYSIS OF STEM CELLS AND GERM CELL DEVELOPMENT IN DROSOPHILA AND MOUSE. 18. C. RON YU, PHD, INVESTIGATOR, JOINED SIMR IN 2005 FROM THE LABORATORY OF RICHARD AXEL, MD, AT COLUMBIA UNIVERSITY CENTER FOR NEUROBIOLOGY AND BEHAVIOR WHERE HE HELD A NATIONAL INSTITUTES OF HEALTH MENTORED RESEARCH SCIENTIST AWARD FROM THE NATIONAL INSTITUTE OF MENTAL HEALTH. YU EARNED HIS PHD IN MOLECULAR, CELLULAR, AND BIOPHYSICAL STUDIES AT COLUMBIA UNIVERSITY. RESEARCH FOCUS: HOW OLFACTORY SENSORY INFORMATION IS DETECTED, INTEGRATED, AND PROCESSED IN THE BRAIN TO INFLUENCE SPECIFIC INNATE BEHAVIORS. 19. SARAH ZANDERS, PHD, ASSISTANT INVESTIGATOR AND VICE DEAN OF THE GRADUATE SCHOOL, JOINED SIMR IN 2016 AFTER COMPLETION OF HER POSTDOCTORAL TRAINING IN BASIC SCIENCES AT THE FRED HUTCHINSON CANCER RESEARCH CENTER (FHCRC) WITH SUPPORT FROM A PATHWAY TO INDEPENDENCE AWARD FROM THE NATIONAL INSTITUTES OF HEALTH. FHCRC FACULTY MEMBERS HARMIT S. MALIK, PHD, AND GERRY SMITH, PHD, ADVISED HER RESEARCH ON FERTILITY, GENOME EVOLUTION, AND THE ORIGIN OF NEW SPECIES. ZANDERS RECEIVED HER PHD IN GENETICS AND DEVELOPMENT FROM CORNELL UNIVERSITY. RESEARCH FOCUS: THE EFFECTS OF GENETIC CONFLICTS CAUSED BY SELFISH GENES THAT ARE EMBEDDED IN EUKARYOTIC GENOMES. 20. JULIA ZEITLINGER, PHD, INVESTIGATOR, JOINED SIMR IN 2007 FROM THE LAB OF RICHARD YOUNG, PHD, AT THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH AT MASSACHUSETTS INSTITUTE OF TECHNOLOGY WHERE SHE WAS THE RECIPIENT OF A LONG-TERM POSTDOCTORAL FELLOWSHIP FROM THE HUMAN FRONTIER SCIENCE PROGRAM. ZEITLINGER EARNED A PHD IN MOLECULAR BIOLOGY FROM THE EUROPEAN MOLECULAR BIOLOGY LABORATORY IN HEIDELBERG, GERMANY. RESEARCH FOCUS: ANALYSIS OF THE GENE REGULATORY NETWORKS UNDERLYING CELLULAR DIFFERENTIATION. TECHNOLOGY CENTERS 1. PAUL KULESA, PHD, DIRECTOR OF IMAGING, JOINED SIMR IN 2002 AFTER COMPLETING A BURROUGHS WELLCOME FUND POSTDOCTORAL FELLOWSHIP IN THE LABORATORY OF SCOTT E. FRASER, PHD, AT THE CALIFORNIA INSTITUTE OF TECHNOLOGY. KULESA RECEIVED A PHD IN APPLIED MATHEMATICS UNDER J.D. MURRAY, PHD, AT THE UNIVERSITY OF WASHINGTON. RESEARCH FOCUS: CELL MIGRATION IN DEVELOPMENT AND CANCER. 2. MICHAEL WASHBURN, PHD, DIRECTOR OF PROTEOMICS, JOINED SIMR IN 2003 FROM THE TORREY MESA RESEARCH INSTITUTE IN SAN DIEGO WHERE HE WAS A SENIOR STAFF SCIENTIST IN PROTEOMICS. HE EARNED A PHD IN BIOCHEMISTRY AND ENVIRONMENTAL TOXICOLOGY FROM MICHIGAN STATE UNIVERSITY BEFORE COMPLETING A POSTDOCTORAL FELLOWSHIP WITH JOHN YATES III, PHD, IN THE DEPARTMENT OF MOLECULAR BIOTECHNOLOGY AT THE UNIVERSITY OF WASHINGTON. RESEARCH FOCUS: QUANTITATIVE PROTEOMICS AND PROTEIN COMPLEX DYNAMICS.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2020

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
MediumBullet

Attach to Form 990.
MediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2020

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity

Part II

Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No
(1)STOWERS SCIENTIFIC EDUCATION INSTITUTE 1000 EAST 50TH STREET KANSAS CITY,MO64110 20-5916445	SUPPORT ORG	DE	501(C)(3)	12A, I	SIMR	Yes
(2)STOWERS RESOURCE MANAGEMENTINC 1000 EAST 50TH STREET KANSAS CITY,MO64110 41-2186719	SUPPORT ORG	DE	501(C)(3)	12A, I	SIMR	Yes
(3)BIOMED VALLEY CORPORATION 1000 EAST 50TH STREET KANSAS CITY,MO64110 74-3238244	SUPPORT ORG	DE	501(C)(3)	12A, I	SIMR	Yes
(4)STOWERS REAL ESTATE HOLDING CORPORATION 1000 EAST 50TH STREET KANSAS CITY,MO64110 26-1472230	TITLE HOLDING	DE	501(C)(2)	N/A	SRM	Yes
(5)STOWERS POLICY INSTITUTE INC 100O EAST 50TH STREET KANSAS CITY,MO64110 20-3270502	SEE PART VII	DE	501(C)(4)	N/A	SIMR	Yes
(6)THE GRADUATE SCHOOL OF SIMR 1000 EAST 50TH STREET KANSAS CITY,MO64110 46-4588696	EDUCATION	MO	501(C)(3)	2	SIMR	Yes

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2020

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No	(k) Percentage ownership

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	Yes	No
(1) BIOMED VALLEY DISCOVERIESINC 1000 EAST 50TH STREET KANSAS CITY,MO64110 06-1646533	SEE PART VII	DE	BVC	C CORP	0	0		Yes

Schedule R (Form 990) 2020

Page 3

Part V

Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity .....................

Yes

b Gift, grant, or capital contribution to related organization(s) ............................

c Gift, grant, or capital contribution from related organization(s) ............................

Yes

d Loans or loan guarantees to or for related organization(s) ............................

e Loans or loan guarantees by related organization(s) ............................

f Dividends from related organization(s) ............................

g Sale of assets to related organization(s) ............................

h Purchase of assets from related organization(s) ............................

i Exchange of assets with related organization(s) ............................

j Lease of facilities, equipment, or other assets to related organization(s) .......................

Yes

k Lease of facilities, equipment, or other assets from related organization(s) ......................

Yes

l Performance of services or membership or fundraising solicitations for related organization(s) .....................

m Performance of services or membership or fundraising solicitations by related organization(s) .................

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) ...................

Yes

o Sharing of paid employees with related organization(s) ............................

Yes

p Reimbursement paid to related organization(s) for expenses ............................

Yes

q Reimbursement paid by related organization(s) for expenses ............................

Yes

r Other transfer of cash or property to related organization(s) ............................

Yes

s Other transfer of cash or property from related organization(s) ............................

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1) BIOMED VALLEY DISCOVERIES INC	A	990,074	MARKET VALUE
(2) BIOMED VALLEY DISCOVERIES INC	A	15,597	MARKET VALUE
(3) STOWERS RESOURCE MANAGEMENT INC	C	61,000,000	MARKET VALUE
(4) STOWERS REAL ESTATE HOLDING CORP	K	2,230,551	MARKET VALUE
(5) STOWERS RESOURCE MANAGEMENT INC	P	23,470,819	COST REIMB.
(6) THE GRADUATE SCHOOL OF SIMR	P	1,026,478	COST REIMB.
(7) BIOMED VALLEY DISCOVERIES INC	P	384,852	COST REIMB.
(8) BIOMED VALLEY DISCOVERIES INC	Q	243,371	COST REIMB.
(9) THE GRADUATE SCHOOL OF SIMR	R	1,458,200	MARKET VALUE
(10) SEE PART VII FOR ADDITIONAL INFORMATION

Schedule R (Form 990) 2020

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No	(k) Percentage ownership

Schedule R (Form 990) 2020

Page 5

Part VII

Supplemental Information

Provide additional information for responses to questions on Schedule R. See instructions.

Return Reference	Explanation
PART II, LINE (5), COLUMN B:	STOWERS POLICY INSTITUTE INC'S. ("SPI") PRIMARY ACTIVITY IS TO PROMOTE INNOVATIVE AND ETHICAL BIOMEDICAL RESEARCH, THERAPIES AND CURES, AND TO ADVOCATE FOR A POLITICAL, ECONOMIC AND SOCIAL ENVIRONMENT THAT ADVANCES, FACILITATES, AND PROTECTS THAT RESEARCH AND THOSE THERAPIES AND CURES.
PART IV, LINE (1), COLUMN B:	BIOMED VALLEY DISCOVERIES, INC.'S ("BVD") PRIMARY ACTIVITY IS THE DEVELOPMENT AND MARKETING OF SCIENTIFIC DISCOVERIES. BIOMED VALLEY CORPORATION ("BVC") IS THE 100% OWNER OF BVD STOCK.
PART V, LINE 2 (1) BVD:	TYPE A, SIMR RECEIVES ROYALTY PAYMENTS FROM BVD PURSUANT TO A LICENSED TECHNOLOGY AGREEMENT DATED JANUARY 29, 2006. THESE ROYALTY PAYMENTS DO NOT CONSTITUTE GROSS INCOME DERIVED FROM AN UNRELATED TRADE OR BUSINESS UNDER SECTION 512(B)(13). THE ROYALTY PAYMENTS FROM BVD TO SIMR DO NOT REDUCE BVD'S TAXABLE INCOME, WHICH WOULD HAVE BEEN UNRELATED BUSINESS INCOME IF BVD WERE EXEMPT UNDER SECTION 501(C)(3) AND HAD THE SAME EXEMPT PURPOSE AS SIMR. IN ADDITION, THE SPECIAL RULE UNDER 512(B)(13)(E) APPLIES.
PART V, LINE 2 (2) BVD:	TYPE A, SIMR RECEIVES SUBLEASE PAYMENTS FROM BVD BASED ON COST FOR LESS THAN 300 SQ FT OF SPACE FOR A LIMITED USE PURPOSE. THE RENT PAYMENTS FROM BVD TO SIMR DO NOT REDUCE BVD'S TAXABLE INCOME WHICH WOULD HAVE BEEN UBTI IF BVD WERE EXEMPT UNDER 501(C)(3) AND HAD THE SAME EXEMPT PURPOSE AS SIMR. THEREFORE, NO PORTION OF THE RENT PAYMENTS FROM BVD CONSTITUTES UNRELATED BUSINESS INCOME TO SIMR UNDER SECTION 512(B)(13).
PART V, LINE 2 (3) SRM:	TYPE C, SRM PROVIDED FINANCIAL SUPPORT TO SIMR TO BE USED BY SIMR IN FURTHERANCE OF SIMR'S EXEMPT PURPOSE OF CONDUCTING MEDICAL RESEARCH.
PART V, LINE 2, (4) SREHC	TYPE K, SIMR ENTERED INTO A LEASE EFFECTIVE JANUARY 1, 2009 WITH SREHC, A 501(C)(2) TAX EXEMPT ORGANIZATION THAT IS A RELATED PARTY TO SIMR. THE LEASE HAS AN ORIGINAL TERM OF 10 YEARS WITH A PROVISION FOR ADDITIONAL OPTION YEARS FOR A 280,000 SQUARE FEET BUILDING. REFLECTS SIMR'S LEASE PAYMENTS TO SREHC IN 2020.
PART V, LINE 2, (5) SRM	TYPE P, SIMR REIMBURSED SRM FOR COSTS ASSOCIATED WITH SRM'S ADMINISTRATIVE AND SUPPORT SERVICES PROVIDED TO SIMR. SRM IS A SUPPORTING ORGANIZATION TO SIMR.
PART V, LINE 2, (6) GSSIMR	TYPE P, SIMR REIMBURSED GSSIMR FOR CERTAIN STUDENT EXPENSES INCURRED DURING TIME SPENT IN SIMR LABS.
PART V, LINE 2, (7) BVD	TYPE P, SIMR REIMBURSED BVD FOR SERVICES ON THE SERVICE COST METHOD.
PART V, LINE 2, (8) BVD	TYPE Q, BVD REIMBURSED SIMR FOR SERVICES ON THE SERVICE COST METHOD.
PART V, LINE 2, (9) GSSIMR	ALL OTHER TRANSACTIONS FOR LINE 1 WERE BETWEEN 501(C)(3) PUBLIC CHARITIES AND BELOW REPORTING THRESHOLDS.
PART V, LINE 2, (10):	ALL OTHER TRANSACTIONS FOR LINE 1 WERE BETWEEN 501(C)(3) PUBLIC CHARITIES AND BELOW REPORTING THRESHOLDS.

Schedule R (Form 990) 2020

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: SIMR'S EXEMPT PURPOSE IS TO PERFORM MEDICAL RESEARCH IN THE PUBLIC INTEREST WITH THE GOAL OF EXPANDING OUR UNDERSTANDING OF THE FUNDAMENTAL PROCESSES OF LIVING CELLS.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	8
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	3
5	Total number of individuals employed in calendar year 2020 (Part V, line 2a) ......	5	365
6	Total number of volunteers (estimate if necessary) .............	6	3
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, line 39 .........	7b

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	69,501,308	67,837,629
9	Program service revenue (Part VIII, line 2g) .........	174,675	177,758
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	2,937,748	1,913,300
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	835,747	1,064,141
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	73,449,478	70,992,828
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	0	0
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	36,569,659	36,620,810
16a	Professional fundraising fees (Part IX, column (A), line 11e) .....	0	0
b	Total fundraising expenses (Part IX, column (D), line 25) 0
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	55,133,761	50,278,644
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	91,703,420	86,899,454
19	Revenue less expenses. Subtract line 18 from line 12.......	-18,253,942	-15,906,626
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	312,071,612	290,225,349
21	Total liabilities (Part X, line 26).............	101,229,740	95,553,948
22	Net assets or fund balances. Subtract line 21 from line 20.....	210,841,872	194,671,401

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 78,355,329 including grants of $ 0 ) (Revenue $ 177,758 )
	SIMR'S ACCOMPLISHMENTS ARE DESCRIBED IN SCHEDULE O.

4b	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )












4c	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )












4d	Other program services (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses78,355,329

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)...........	3,186,702	7,258,738	667,163

(A) Name and business address	(B) Description of services	(C) Compensation
AMERICAN CENTURY INVESTMENTS, 4500 MAIN ST KANSAS CITY,MO64111	INDIRECT - SEE SCH O	145,000




2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 1

1a	Federated campaigns..		1a	0
b	Membership dues..		1b	0
c	Fundraising events..		1c	0
d	Related organizations		1d	61,100,000
e	Government grants (contributions)		1e	6,165,050

f	All other contributions, gifts, grants, and similar amounts not included above		1f	572,579

g	Noncash contributions included in lines 1a - 1f:$		1g	61,100,000

h Total. Add lines 1a-1f.......		67,837,629

		Business Code
2a	COLLABORATION FEE FROM HHMI 501(C)(3)	900099	177,758	177,758
b
c
d
e
f	All other program service revenue.
g	Total. Add lines 2a–2f .....		177,758

3 Investment income (including dividends, interest, and othersimilar amounts) ......			913,889			913,889
4 Income from investment of tax-exempt bond proceeds			0
5 Royalties...........			1,010,074			1,010,074
		(ii) Personal	(i) Real
6a	Gross rents		15,598	6a
b	Less: rental expenses		15,598	6b
c	Rental income or (loss)	0	0	6c
d	Net rental income or (loss).......			0
		(ii) Other	(i) Securities
7a	Gross amount from sales of assets other than inventory	24,688	89,765,731	7a
b	Less: cost or other basis and sales expenses	46,381	88,744,627	7b
c	Gain or (loss)	-21,693	1,021,104	7c
d	Net gain or (loss).........			999,411			999,411
8a	Gross income from fundraising events (not including $ of contributions reported on line 1c). See Part IV, line 18 ....
			8a	0
b	Less: direct expenses ...		8b	0
c	Net income or (loss) from fundraising events..			0
9a	Gross income from gaming activities. See Part IV, line 19 ...
			9a	0
b	Less: direct expenses ...		9b	0
c	Net income or (loss) from gaming activities..			0
10a	Gross sales of inventory, less returns and allowances ..
			10a	0
b	Less: cost of goods sold ..		10b	0
c	Net income or (loss) from sales of inventory..			0
Business Code			Miscellaneous Revenue
11a	OTHER REBATES & REVENUE		900099	54,067			54,067
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			54,067
12	Total revenue. See instructions.....			70,992,828	177,758		2,977,441

1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 ....	0
2	Grants and other assistance to domestic individuals. See Part IV, line 22 ...........	0
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. .............	0
4	Benefits paid to or for members .......	0
5	Compensation of current officers, directors, trustees, and key employees ...........	1,357,478	1,221,730	135,748	0
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .........	776,062	698,456	77,606	0
7	Other salaries and wages........	25,287,732	22,758,959	2,528,773	0
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	2,630,079	2,367,071	263,008	0
9	Other employee benefits .......	4,726,073	4,253,466	472,607	0
10	Payroll taxes ...........	1,843,386	1,659,047	184,339	0
11	Fees for services (non-employees):
a	Management ......	0
b	Legal .........	0
c	Accounting ...........	0
d	Lobbying ...........	0
e	Professional fundraising services. See Part IV, line 17	0
f	Investment management fees ......	0
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)	1,726,982	1,554,284	172,698	0
12	Advertising and promotion ....	0
13	Office expenses .......	100,106	90,095	10,011	0
14	Information technology ......	300,987	270,888	30,099	0
15	Royalties ..	503,920	453,528	50,392	0
16	Occupancy ...........	2,214,953	1,993,458	221,495	0
17	Travel ............	127,746	114,971	12,775	0
18	Payments of travel or entertainment expenses for any federal, state, or local public officials .	0
19	Conferences, conventions, and meetings ....	247,302	222,572	24,730	0
20	Interest ...........	0
21	Payments to affiliates .......	0
22	Depreciation, depletion, and amortization ..	9,457,695	8,511,926	945,769	0
23	Insurance ...	0
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	COST-SHARING W/RELATED ORG	28,197,344	25,377,610	2,819,734
b	LAB SUPPLIES	5,501,867	4,951,680	550,187
c	PER CAPITA APPROP. TO GSSIMR	1,458,200	1,458,200	0
d	COLLABORATION EXPENSE	218,998	197,098	21,900
e	All other expenses	222,544	200,290	22,254
25	Total functional expenses. Add lines 1 through 24e	86,899,454	78,355,329	8,544,125	0
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).

1	Cash–non-interest-bearing ........			0	1	0
2	Savings and temporary cash investments .........			937,906	2	2,211,333
3	Pledges and grants receivable, net ......			470,714	3	716,001
4	Accounts receivable, net .............			0	4	0
5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
				0	5	0
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
				0	6	0
7	Notes and loans receivable, net ...........			0	7	0
8	Inventories for sale or use ............			2,627	8	2,593
9	Prepaid expenses and deferred charges ......			375,470	9	368,643
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	334,055,041
b	Less: accumulated depreciation	10b	202,980,462	138,326,879	10c	131,074,579
11	Investments—publicly traded securities .			85,997,459	11	74,130,819
12	Investments—other securities. See Part IV, line 11 .....			448,431	12	601,654
13	Investments—program-related. See Part IV, line 11 ..			0	13	0
14	Intangible assets ...............			0	14	0
15	Other assets. See Part IV, line 11 ...........			85,512,126	15	81,119,727
16	Total assets. Add lines 1 through 15 (must equal line 33)...			312,071,612	16	290,225,349

17	Accounts payable and accrued expenses .....	9,773,789	17	8,050,210
18	Grants payable ...	0	18	0
19	Deferred revenue .........	334,266	19	505,886
20	Tax-exempt bond liabilities .........	0	20	0
21	Escrow or custodial account liability. Complete Part IV of Schedule D	0	21	0
22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
		0	22	0
23	Secured mortgages and notes payable to unrelated third parties ..	0	23	0
24	Unsecured notes and loans payable to unrelated third parties ..	0	24	0
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	91,121,685	25	86,997,852
26	Total liabilities. Add lines 17 through 25..	101,229,740	26	95,553,948

	Organizations that follow FASB ASC 958, check here and complete lines 27, 28, 32, and 33.
27	Net assets without donor restrictions ..........	210,635,494	27	194,462,394
28	Net assets with donor restrictions ...........	206,378	28	209,007
	Organizations that do not follow FASB ASC 958, check here and complete lines 29 through 33.
29	Capital stock or trust principal, or current funds .....		29
30	Paid-in or capital surplus, or land, building or equipment fund ...		30
31	Retained earnings, endowment, accumulated income, or other funds		31
32	Total net assets or fund balances ...........	210,841,872	32	194,671,401
33	Total liabilities and net assets/fund balances ........	312,071,612	33	290,225,349